PF-[ADDRESS_626994] Number: PF-[ADDRESS_626995] Name: [CONTACT_488067] (N/A)
[LOCATION_002] (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:2018-004669-16
Protocol Number: C2501004
Phase: 2b
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] must be promptly notified.
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document Version Date Summary of Changes and Rationale
Amendment 1 01 October 2019 1.Amendment 1 has become necessary  to 
update the contraception language and to 
align with emerging development of 
program safety requirements (protocol 
C2501003 for ulcerative colitis).  
Rationale: the purpose of the update is to 
mitigate a theoretical risk of CYP3A 
induction by  [INVESTIGATOR_16335]-06826647 and thereb y 
potentially  lowering the efficacy  of 
hormonal contraceptives.  Given the 
potential teratogenicit y risk of 
PF-06826647, the addition of a barrier 
method for female participants on hormonal 
contraception is included. 
Since the expected maximum change in 
exposure based on fracti on metabolized [ fm] 
value is approximately  2-fold, the 
ethiny lestradiol containing contraceptives 
are now allowed.  See Section 4.3, 5.3.1 & 
Appendix 10.4.2 and 10.4.4 for details.  
2.Removed body  mass index (BMI) s ee 
Section 5.1 I nclusion Criteria #6.
Rationale: I t does not impact PK or PD.
3.Added two exclusion criteria see 
Section 5.2 Exclusion Criteria : 
#13. History  of recurrent ( >2) venous 
thrombosis or any  arterial 
thromboembolism or known blood clotting 
disorders.
#14. History  of acute coronary  syndrome 
(eg, my ocardial infarction, unstable angina 
pectoris) and an y history of cerebrovascular 
disease within 24 weeks before screening.
Rational: to clarify and provide more 
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 3specific language on the criteria.
4. A dded language to Discontinuation of
Study  Intervention involving
thromboembolic events see Section 7.1 .
Rationale: to provide consistency  across the 
program.
5. A dded language to Safety  Adjudication 
Committee Section 9.5.2.
Rational: to align with program language to 
specificall y include events requi ring 
adjudication are cardiovascular events 
including venous thromboembolic events 
(VTE).
6.The content of five Protocol Administrative 
Clarification Letters (PACL s) # 1- 5 was 
added.
PACL  1:1) HIV serology  should also 
include Hep B tests as described in 
EC#21.  2) Appendix 2 should include 
the above.  3) PROs should be 
completed in a certain same order 
(preand post Day  15).
Rationale: to ensure consistency  throughout 
protocol.
PACL  2: typographical error of absolute 
lymph count (should be 1000 not 800).
Rationale: clarification.
PACL  3 JAPAN Only :EC #23clarified 
subjects will have HBV DNA testing if 
there is no documentation of HBV 
vaccination.
Rationale: country  requirement.
PACL  4: Concomitant medications 
guselkumab and risankizumab were 
added to the agents requiring 6- month 
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 4washout.
Rationale: frequentl y asked question by 
[CONTACT_488037].
PACL  5:1) C-SSRS footnote to clarify  
the use of “Lifetime” version at 
baseline.  2) PRO footnote to clarify  
pre-dose to be consistent with other 
sections.  3) discrepancy  clarified that 
no live vaccines allowed [ADDRESS_626996] dose.  4) Justification for Dose 
section 4.3 discrepancy  corrected to 
confirm 83% not 82%.
Rationale: to ensure consistency  throughout 
protocol.
Additional discrepancies were 
eliminated, and typographical errors 
corrected.
Original protocol 14December 2018 N/A
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and institutional review boards (I RBs)/ethics committees 
(ECs).
PF-[ADDRESS_626997] OF TABLES................................................................................................................. ..10
1. PROTOCOL  SUMMARY...................................................................................................11
1.1. Synopsis .................................................................................................................. 11
1.2. Schema .................................................................................................................... 16
1.3. Schedule of Activities (SoA)...................................................................................17
2. INTRODUCTION ...............................................................................................................2 1
2.1. Study R ationale .......................................................................................................21
2.2. Background .............................................................................................................21
2.2.1. Non-Clinical Safety Studies with PF-06826647.........................................222.2.2. Non-Clinical Pharmacokinetics and Metabolism .......................................222.2.3. Clinical Overview.......................................................................................23
2.3. Benefit/Risk Assessment.........................................................................................25
3. OBJECTIVES, ESTIMANDS, AND ENDPOINTS ...........................................................26
3.1. Study Objectives, Endpoints and Estimands -- Investigational Treatment 
Period......................................................................................................................... 26
4. STUDY DESIGN................................................................................................................ .31
4.1. Overall Design.........................................................................................................314.2. Scientific Rationale for Study Design.....................................................................324.3. Justification for Dose ..............................................................................................334.4. End of Study Definition ..........................................................................................35
5. STUDY POPULATION ......................................................................................................36
5.1. Inclusion Criteria.....................................................................................................365.2. Exclusion Criteria....................................................................................................375.3. Lifestyle Cons iderations..........................................................................................41
5.3.1. Contraception..............................................................................................425.3.2. Vaccination.................................................................................................425.3.3. Other Lifestyle Requirements.....................................................................43
5.4. Screen Failures ........................................................................................................44
6. STUDY INTERVENTION..................................................................................................44
6.1. Study Intervention(s) Administered ........................................................................44CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 66.1.1. Administration ............................................................................................46
6.2. Preparation/Handling/Storage/Accountability ........................................................[ADDRESS_626998] Supplies ........................................48
6.3. Measures to Minimize Bias: Randomization and Blinding.....................................[ADDRESS_626999] .........................................................496.3.2. Breaking the Blind......................................................................................49
6.4. Study Intervention Compliance...............................................................................506.5. Concomitant Therapy..............................................................................................50
6.5.1. Rescue Medicine.........................................................................................52
6.6. Dose Modification...................................................................................................526.7. Intervention after the End of the Study ...................................................................53
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL...........................................................................53
7.1. Discontinuation of Study Intervention ....................................................................537.2. Participant Discontinuation/Withdrawal from the Study........................................547.3. Lost to Follow-up ....................................................................................................56
8. STUDY ASSESSMENTS AND PROCEDURES...............................................................56
8.1. Efficacy Assessments..............................................................................................57
8.1.1. Psoriasis Area and Severity Index (PASI)..................................................578.1.2. Physician Global Assessment (PGA) .........................................................60
8.1.4. Rater Qualifications....................................................................................62
8.2. Safety Assessments .................................................................................................62
8.2.1. Assessments at Screening only...................................................................63
[IP_ADDRESS]. Tuberculosis (TB) Testing ........................................................[IP_ADDRESS]. Chest Radiograph ......................................................................[IP_ADDRESS]. Medical History.........................................................................[IP_ADDRESS]. Suicidal Ideation and Behavior Risk Monitoring......................64
8.2.2. Assessment During Study...........................................................................64
[IP_ADDRESS]. Full Physical and Brief Physical Examinations ........................64
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Weight and Height ....................................................................64
[IP_ADDRESS]. Vital Signs (Blood pressure, pulse rate, and temperature)........65
8.2.3. Electrocardiograms.....................................................................................658.2.4. Clinical Safety La boratory Asse ssments ....................................................66
8.2.5. Suicidal Ideation and Behavior Risk Monitoring .......................................66
[IP_ADDRESS]. Columbia Suicide Severity Rating Scale ..................................67
8.2.6. Herpetiform Rash Surveillance...................................................................678.2.7. Glomerular Filtration Rate..........................................................................678.2.8. Pregnancy Testing ......................................................................................67
8.3. Adverse Events and Serious Adverse Events..........................................................68
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......68
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................69
8.3.2. Method of Detecting AEs and SAEs ..........................................................698.3.3. Follow-up of AEs and SAEs.......................................................................698.3.4. Regulatory Reporting Requirements for SAEs...........................................698.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure ..........................................................................................................70
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................70
8.3.6. Medication Errors .......................................................................................70
8.4. Treatment of Overdose............................................................................................71
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 88.9. Health Economics ...................................................................................................75
8.10. Patient Reported Outcome Measures ....................................................................75
8.10.1. Psoriasis Symp tom Inve ntory...................................................................76
8.10.2. Peak-Pruritus Numerical Rating Scale .....................................................76
9. STATISTICAL C ONSIDERATIONS ................................................................................77
9.1. Estimands and Statistical Hypotheses .....................................................................77
9.1.1. Estimands....................................................................................................77
9.2. Sample Size Determination.....................................................................................789.3. Populations for Analysis .........................................................................................789.4. Statistical Analyses .................................................................................................78
9.4.1. Efficacy Analyses .......................................................................................799.4.2. Safety Analys es ..........................................................................................80
[IP_ADDRESS]. Electrocardiogram Analyses......................................................80
9.5. Interim Analyses .....................................................................................................81
9.5.1. Data Monitoring Committee.......................................................................819.5.2. Safety Adjudication Committees................................................................82
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................83
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............83
10.1.1. Regulatory and Ethical Considerations ....................................................83CCI
CCI
CCI
CCICCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................83
10.1.2. Financial Disclosure .................................................................................8410.1.3. Informed Consent Process ........................................................................8410.1.4. Data Protection .........................................................................................8510.1.5. Dissemination of Clinical Study Data ......................................................8510.1.6. Data Qualit y Assurance ............................................................................87
10.1.7. Source Documents....................................................................................8810.1.8. Study and Site Closure..............................................................................89
10.1.9. Publication Policy.....................................................................................8910.1.10. Sponsor’s Qualified Medical Personnel .................................................90
10.2. Appendix 2: Clinical Laboratory Tests .................................................................9110.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................92
10.3.1. Definition of AE .......................................................................................9210.3.2. Definition of SAE.....................................................................................9310.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.......................9410.3.4. Reporting of SAEs....................................................................................97
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information ................................................................................................................99
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................9910.4.2. Female Participant Reproductive Inclusion Criteria.................................9910.4.3. Woman of Childbearing Potential (WOCBP) ..........................................9910.4.4. Contraception Methods...........................................................................100
10.5. Appendix 5: Genetics ..........................................................................................[ZIP_CODE].6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ......[ZIP_CODE].7. Appendix 7: ECG Findings of Potential Clinical Concern .................................[ZIP_CODE].8. Appendix 8: Prohibited Concomitant Medications.............................................[ZIP_CODE].9. Appendix 9: Columbia Suicide Severity Rating Scale (C-SSRS) for 
Screening and Baseline Visit...................................................................................112
10.10. Appendix 10: Psoriasis Symptom Inventory (PSI) (Daily Assessment)...........116
10.11. Appendix 11: Peak Pruritus Numeric Rating Scale (PP-NRS) .........................118
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 1010.17. Appendix 17: Physician Global Assessment.....................................................130
10.18. Appendix 18: eGFR Calculations .....................................................................[ZIP_CODE].19. Appendix 19: Abbreviations .............................................................................[ADDRESS_627000] OF TABLES
 
 
Table 4. Psoriasis Area and Severity Index (PASI) Area Score Criteria................58
Table 5. Psoriasis Area and Severity Index (PASI) Area Score Criteria................59Table 6. Component Scoring Criteria for the Physician's Global Assessment 
(PGA)........................................................................................................60
Table 7. Physician's Global Assessment (PGA) Score...........................................61Table 8. Handprint Determination of Body Region Surface Area .........................61CCI
CCI
CCI
CCICCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 111.PROTOCOL SUMMARY 
1.1.Synopsis 
Rationale :This multicenter study  is being con ducted to provide additional PF -[ADDRESS_627001] ore the clinical efficacy  of PF -06826647 in the 
treatment of moderate to severe plaque psoriasis.  Additionally , the study  is intended to 
enable selection of oral dose and dosing regimen for the fu ture clinical development of 
PF-06826647.
Objectives ,Endpoints , and Estimands :
Investigational Treatment Period:
Objectives Endpoints Estimands
Prim ary: Prim ary: Prim ary: 
To compare the efficacy of multiple 
dose levels of PF -06826647 versus 
placebo on the proportion of 
participants with moderate to severe 
plaque psoriasis achieving PASI 90.Proportion of participant s 
achieving PASI 90 
(90% or greater 
improvement from 
Baseline) at Week 16.Estimand E1:
This estimand is intended to 
provide a population level estimate 
of the treatment effect of the IP 
alone on a binary responder 
endpoint; without the benefit of 
additional prohibited medications, 
regardless of participants 
compliance with the IP dosing.
Population: Particip ants with 
moderate to severe plaque 
psoriasis as defined by [CONTACT_488038] .
Intercurrent Events: A) Prohibited 
medication –response will be 
considered ne gative for 
participants after receiving 
prohibited medication.   
B)Withdraw al and all other events 
leading to missing data will be 
treated as in A.   C)Inadequate 
compliance –participants data w ill 
be used as recorded.
Population level summary: The 
differ ence in proportions between 
treated and placebo response rates .
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 12Secondary: Secondary: Secondary: 
To compare the efficacy of multiple 
dose levels of PF -06826647 versus 
placebo on the proportion of 
participants with moderate to severe 
plaque psoriasis achieving PASI 75.Key secondary endpoint :
Proportion of participants 
achieving PASI 75 
(75% or greater 
improvement from 
Baseline) at time points 
specified in the Schedule 
of Activities (SoA) .The binary secondary endpoints, 
when appropriate, w ill be analyzed 
descriptively and using estimand 
E1.
To compare the efficacy of multiple 
dose levels of PF -06826647 versus 
placebo on PGA score in participants 
with moderate to severe plaque 
psoriasis .Proportion of participants 
with PGA score clear (0)
or almost clear (1) and 
≥2points improvement 
from baseline at time 
points specified in the 
SoA.
Proportion of participants 
with PGA score clear (0) 
or almost clear (1) at time 
points specified in the 
SoA.
To compare the efficacy of multiple 
dose levels of PF -06826647 versus 
placebo on the proportion of 
participants with moderate to severe 
plaque psoriasis achieving PASI 50 and 
PASI 100.Proportion of participants 
achieving PASI 50 
(50% or greater 
improvement from 
Baseline), PASI 100 
(100% from Baseline) at 
time points specified in 
the SoA.
To compare the efficacy of multiple 
dose levels of PF -06826647 versus 
placebo on PGA and PASI scores in 
participants with moderate to severe 
plaque psoriasis .Change from baseline and 
percent change from 
baseline in PASI scores at 
time points specified in 
the SoA.Estimand E2: 
This estimand is intended to 
provide a population level estimate 
of the treatment effect of the IP 
alone on a continuous endpoint; 
without the benefit of additional 
prohibited medications, regardless 
of participants compliance with 
the IP dosing.
Population: Participants with 
moderate to severe plaque 
psoriasis as defined by [CONTACT_488039] .
Intercurrent Events: A) Prohibited 
medication –all scores after 
participants receive prohibited To compare the effect of multiple dose 
levels of PF -06822647 versus placebo 
in Peak -Pruritus Numerical Rating 
Scale score in participants with 
moderate to severe plaque psoriasis.Absolute score and 
change from baseline in 
Peak -Pruritus Numerical 
Rating Scale score at time 
points specified in the 
SoA.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 13medicat ion will be omitted from 
the analysis and treated as missing 
scores.   Missing scores will be 
imputed based on the assumption 
that participants do not benefit 
from the IP treatment. 
B)Withdraw al and all other events 
leading to missing data will be 
treated similarly as in A.
C)Inadequate compliance –
participants data will be used as 
recorded.
Population level summary: 
The mean difference between 
treated and placebo arms of the 
change from baseline PASI score.
All continuous endpoint, when 
appropriate wi ll be analyzed 
descriptively and using estimand E2 
described above when appropriate .
To assess the safety and tolerability of 
PF-06826647 in participants with 
moderate to severe plaque psoriasis.Incidence and severity of 
adverse events, serious 
adverse events and 
withdrawals due to 
adverse events. 
Change from baseline in 
clinical laboratory values 
(chemistry and 
hematology, lipi[INVESTIGATOR_805]).
Incidence of clinically 
significant changes in 
ECG (heart rate, QT, 
QTc, PR and QRS 
intervals). 
Change from baseline in 
vital signs (blood 
pressure, pulse rate and 
temperature 
measurements).There is no defined estimand for 
these endpoints and they will be 
analyzed using [COMPANY_007] dat a standards 
as applicable .
To compare the efficacy of multiple 
dose levels PF -06826647 versus 
placebo on measures of disease and 
symptom severity in participants with 
moderate to severe plaque psoriasis.Absolute score and 
change from baseline 
Psoriasis Symptom 
Inventory at time points 
specified in the SoA.These endpoints will be analyzed 
descriptively and using estimand E2 
described above when appropriate .
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 14Extension Treatment Period:
Objectives Endpoints Estimands
Prim ary: Prim ary: Prim ary: 
To assess the safety and tolerability of 
PF-06826647 in participants with 
moderate to severe plaque psoriasis.Incidence and severity of 
adverse events, serious 
adverse events and 
withdrawals due to 
adverse events. 
Change from baseline in 
clinical laboratory values 
(chemistry, hematology 
&lipi[INVESTIGATOR_805]).
Incidence of clinically 
significant changes in 
ECG (heart rate, QT , 
QTc, PR and QRS 
intervals). 
Change from baseline in 
vital signs (blood 
pressure, pulse rate and 
temperature 
measurements).Not Applicable- will be analyzed 
descriptively and according to the 
[COMPANY_007] standard .
Overall Design :
This is a Phase 2b, randomized, double blind, placebo controlled, and multicenter study  in 
participants with moderate to severe plaque psoriasis.  Following a Screenin g period of up to 
6weeks , is a 16 week placebo controlled Investigational Treatment Period with double b lind 
oral daily  treatment using the following doses: 50 mg, 100 mg, 200 mg, 400 mg.  All 
participants completing the 16 week Investigational Period may  continue on to a 24 week 
non-placebo controlled Extens ion Treatment Period with double blind oral daily  treatment , if 
per the Investigator judgment the participant is compliant with study  procedures and 
continued participation presents no safet y risks .  The participants continuing into the 
Extension Treatment Period that were origina lly randomized to the 200 mg and 400 mg 
treatment groups will continue on their respective doses, while those randomized to one of 
the other treatment groups (including placebo) will be randomly  assigned (at study  baseline) 
toreceive either 200 mg or 400 mg during the Extension Treatment Period.   The total 
duration of study  participation w ill be approximately  50weeks, including up to 6 weeks 
Screening, 16 week Investi gational Treatment Period, 24 week Extension Treatment Period 
and a Follow -Up visit 4weeks after the Extension Period ends.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 15Number of Participants:
Approximately  160 participants (40 participants in each of the following arms: placebo, 
200mg,and 400 mg;and 20 participants ineach of the following arms: 50 mg and 100 mg) 
will be randomly  assigned to a treatment group in order to ensure a minimum of 
128evaluable participants completing Week 16(assuming a 20% dropout rate) .
Intervention Groups and Duration:
During the Investigational Treatment Period (Weeks 0 through 16) , the 160 participants will 
receive PF -06826647 (50 mg, 100 mg, 200 mg, 400 mg) once dail y, or matching placebo and 
the same participants will continue onto the Extension Treatment Period. 
After completion of the 16 week placebo controlled Investigational Study  Period, participants 
may transition directly  into the 24week Extension Study  Period.
Thetotal duration of study  participation will be approximately  50weeks, including up to 
6weeks Screening, 16 week Investigational Treatment Perio d, the 24 week Extension 
Treatment Period and a Follow -Up visit 4weeks after the Extension Period ends .
Data Monitoring Committee: 
This study  will use an internal review committee (IRC) ( Section 9.5.1 ).
Statistical Methods :
The primary  estimand will be the population average treatment effect on PASI [ADDRESS_627002] to compliance in the absence of prohibited 
medication. 
The anal ysis of the primary  estimand will be of the proportion of participants achieving: 
PASI 75 (75% or greater improvement from Baseline); PGA score clear (0) or almost 
clear (1) and ≥2 points improvement from baseline; PGA score clear (0) or almost clear (1);
PASI 50 (50% o r greater improvement from Baseline) andPASI 100 (100% or greater 
improvement from Baseline).   The anal ysis of the secondary  estimand will be of the change 
from baseline and percent change from baseline in PASI  scores; and absolute score and 
change from baseline in Peak -Pruritus Numerical Rating Scale score.
All other key  secondary  continuous clinical endpoints will be analy zed using the seco ndary  
estimand, while all other key  secondary  categorical clinical endpoints will be anal yzed using 
the primary  estimand.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
1.2.Schema
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 16

PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 171.3. S chedule of Activ ities (SoA)
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  sche dule visits (unplanned visits) in addition to those listed i n the SoA table , in order to conduct evaluations or 
assessments requi red to protect the well- being of the participant
Study Procedure Screening Baseline Investigational Treatment Period Extension Treatment Period Follow -
UpbEarly 
Terminationc
Visit Identifier (Week) -6 to -1 0 1 2 4 6 8 12 16 18/20/24/28/32 /36 40 20 or 44
Study Daya-42to -1 1 8 15 29 43 57 85 113 127/141/169/197/225 /253 281 141 or 309
Visit Window (Days) N/A ±1 ±1 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3
Enrollment Procedures
Informed consent X
Medical history &
demographyX
Eligibility assessment X X
Medication History X
Randomization X
Clinical Assessments
Full Physical Exam X X X X X
Brief Physical Exam X X X X X X X X
Vital signsdX X X X X X X X X X X X X
ECGdX X X X X X
Height/WeighteX X X X
Chest radiographfX
C-SSRSgX X X X
Laboratory Assessments
Hem atology/Blood 
chemistryX X X X X X X X X X X X X
Lipid panelh(fasting) X X X X
UrinalysisiX X X X X
FSHjX
Serum -HCGkX
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 18Study Procedure Screening Baseline Investigational Treatment Period Extension Treatment Period Follow-
UpbEarly 
Terminationc
Visit Identifier (Week) -6 to -1 0 1 2 4 6 8 12 16 18/20/24/28/32/36 40 20 or 44
Study Daya-42 to -1 1 8 15 29 43 57 85 113 127/141/169/197/225/253 281 141 or 309
Visit Window (Days) N/A ±1 ±1 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3
Urine β-HCGl(done at site) X XXXXXXX X X X X
HIV serology/HBsAg, 
HBcAb, (HepB reflex 
testing), and HCVAbmX
Tuberculosis testnX
 
 
Study treatment
IP dispensingqX XXXXXXX X
IP accountability X X X X X X X X X X
Dosing diaryrXXXXXXX X X X
Clinical Assessments of 
psoriasis
PASI, PGA X X X X X X X X X X X X X
PROss
Psoriasis Symptom InventoryXX X X X X X X
tXX X
PP-NRS X X X X X X X XtXX X
 CCI
CCI
CCI
C
CI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 19Study Procedure Screening Baseline Investigational Treatment Period Extension Treatment Period Follow-
UpbEarly 
Terminationc
Visit Identifier (Week) -6 to -1 0 1 2 4 6 8 12 16 18/20/24/28/32/36 40 20 or 44
Study Daya-42 to -1 1 8 15 29 43 57 85 113 127/141/169/197/225/253 281 141 or 309
Visit Window (Days) N/A ±1 ±1 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3
 
Monitoring 
Contraception CheckvX XXXXXXX X X X X
Concomitant Treatment(s) X X X X X X X X X X X X
A E  m o n i t o r i n g X X XXXXXXX X X X X
Abbreviations: AE= adverse event;  C-SSRS= Columbia Suicide Severity Rating Scale;  
ECG = electrocardiogram; FSH= follicle stimulating hormone; HBsAg= hepatitis B surface 
antigen; HBcAb= hepatitis B core antibody; HCVAb= hepatitis C virus antibody; β-HCG= human chorionic gonadotropin; HIV= human immunodeficiency virus; IP = 
Investigational Product; PASI = Psoriasis Area and Severity Index; PP-NRS= Peak-Pruritus Numerical Rating Scale PE= physical exam; PGA= Physician’s Global Assessment; 
PRO = patient reported outcome; WOCBP= women of child-bearing potential.
a. Days relative to Day 1.
b. Perform Follow-Up visit to the Investigational Treatment Period at Week 20 only if the participant does not continue into the Ext ension Treatment Period.  
Otherwise Follow-Up is completed at Week 44.
c. Participants who prematurely withdraw during Investigational Treatment Period or during the Extension Treatment Period should r eturn for an Early 
Termination (ET) visit occurring [ADDRESS_627003] dose whenever possible and continue visits per Investigator’s discretio n until the event has returned 
to normal or baseline levels or is deemed clinically stable.
d. 12-lead locally read singlicate ECG should be performed after the participant has rested quietly for at least [ADDRESS_627004] while preferably sitting (supi[INVESTIGATOR_140730]).  Participants should not smoke or ingest caffeine 30 minutes prior to blood pr essure and pulse rate 
measurements.
e. Height only measured at Screening; height and weight will be measured without shoes.f. Chest X-ray or other appropriate chest diagnostic imaging (ie, CT  or MRI) may be performed within 12 weeks prior to Day 1. 
g. Use C-SSRS “Lifetime” version at Screening and Baseline and “Since Last Visit” version at visits indicated in SoA.  Participants who have recent or active 
suicidal ideation or behaviors will be excluded from study entry or after Day 1, would be discontinued from treatment and referr ed to a mental health 
professional for appropriate evaluation and treatment.
h. Participants must be fasting (water only) for at least 8 hours prior to visits, when lipid panel is being assessed. i. Dipstick in all cases; microscopy analysis is indicated if urinalysis is positive for blood, nitrite, leukocyte esterase and/ or protein.  Urine culture is performed 
if urinalysis is positive for nitrite and/or leukocyte esterase or if clinically indicated.C
CI
CCI
CCI CCICCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 20j. To be done in females (<60 years of age) who are amenorrheic for at least 12 consecutive months. 
k. Required for WOCBP at Screeningl. Required for WOCBP prior to dosing at baseline and at all subsequent visits.  To be conducted at the site.  Pregnancy tests (ser um or urine) may also be 
repeated more frequently as per request of IRBs/ECs or if required by [CONTACT_427]. 
m. HepB reflex testing only if HBsAg negative but HBcAb positive at Screening. If result of HCVAb is positive, or if Hepatitis C  Virus (HCV) antibody result 
is indeterminate, then a HCV RNA AMPLIPREP TAQMAN 2.0 will automatically be performed.  In Japan see Section 5.1 for HBV and HCV details.
n. If not performed within 12 weeks prior to Screening (see Assessments Section [IP_ADDRESS] for details). 
o. PK samples will be collected per SoA prior to dosing, and at 0.5 hour (±5 min); at 1 and 2 hours (±10 min) and 4 hours (±20 min) post dose hours.
q. Participants should take blinded study medication daily during the Investigational Treatment Period and Extension Period; however , on study visit days, 
participants are instructed to refrain from dosing at home, and are to take the dose in the clinic. 
r. Participants will be reminded to complete the dosing diary daily throughout the study.s. All procedures should be performed before dosing of IP.  Effort should be made to complete all PRO questionnaires before any o ther assessments except at 
Baseline when eligibility needs to be confirmed.
t. Psoriasis Symptom Inventory, Peak-Pruritus Numerical Rating Scale  scales to be completed daily for the first two weeks pre -dos ea s
per SoA and at visits Weeks 4, 8, 12, 16, 24, 36 and Follow-up. 
v. To confirm that contraception, if assigned, is used consistently and correctly.C
C
CCI
C
C
I
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 212. INTRODUCTION
PF-06826647 is a potent tyrosine kinase 2 (TYK2) inhibitor with a favorable selectivity 
profile over other human kinases and is being investigated in participants with plaque psoriasis.  Based on its cytokine inhibition profile, PF-06826647 is expected to target theT-helper 1 (Th1), T-helper 17 (Th17), and Ty pes I interferon signaling pathways directly by 
[CONTACT_488040]2. This should provide therapeutic benefit in the treatment of inflammatory conditions driven by [CONTACT_78443]1/Th17 and interferon immune responses.
2.1. Study Rationale
The purpose of this multicenter, placebo controlled double blind study is to provide 
additional efficacy, safety, tolerability  data regarding PF-[ADDRESS_627005] common variant of psoriasis or plaque psoriasis, is a chronic inflammatory 
autoimmune skin disease characterized by [INVESTIGATOR_5697], scaly, raised plaques.  Chronic plaque psoriasis is a common skin disorder with a worldwide prevalence of 2% and afflicts an estimated 7.[ADDRESS_627006] the patient’s quality of life (QoL) resultingin impairment akin to other major diseases, such as diabetes, cardiovascular disease, and psoriatic arthritis.
1
The Janus kinase (JAK) family, which includes JAK1, JAK2, JAK3 and TYK2, is a group of cytoplasmic tyrosine kinases that mediate signal transduction via interactions with Type 1 and Type 2 cytokine receptors critical for immune cell function, survival, activation, and proliferation.
2TYK2 pairs with JAK1 to mediate type I interferon (IFN) signaling and with 
JAK2 to transmit interleukin (IL) IL-[ADDRESS_627007] effective therapeutics are directed to the cytokines and cytokine signaling of inter leukin-23/type 17 T cell (IL-23/T17) axis.
[ADDRESS_627008] article related, 
nonadverse, target organs identified include the immune and hemoly mphatic sy stems 
(thymus, spleen, l ymph nodes, bone marrow, ery thron, and leukon), liver (increas ed 
transaminases), and bone (increased trabecular thickness) .  The findings in the immune and 
hemoly mphatic s ystems are consistent with the pharmacological activity  of PF -06826647.  In 
the 6- month toxicity  study  in rats, the no-observed-adverse- effect leve l (NOAEL) was 
500mg/kg/day  (250 mg/kg BID ) with unbound and total maximum concentration Cmax
values of 1680 and 9360 ng/mL, respectively, and unbound and total AUC 24(area under the 
curve 24 hours) values of 16,600 and 92,000 ng•h/mL , respectivel y.  In the 9 -month toxicity  
study  in monkey s, the NOAEL was 220 mg/kg/day  with unbound and total C maxvalues of 
663 and 1950 ng/mL, respectivel y, and unbound and total AUC 24values of 8130 and 
23,900 ng•h/mL , respectively .  In an embryo fetal development study  inrabbits ,adverse 
PF-06826647 -related embry olethality  due to higher incidence of late resorptions resulting in 
higher postimplantation loss and lower number of l ive fetuses was observed at 
500mg/kg/day  (unbound C maxof 1290 ng/mL  and AUC 24of 17,300 ng•h/ mL).  The 
developmental NO AEL in rats was 500 mg/kg/day  (unbound Cmaxof 1850 ng/mL and AUC 24
of 19,600 ng•h/mL) , and in rabbits was 150 mg/kg/day  (unbound C maxof 864 ng/mL and 
AUC 24of 9930 ng•h/mL ).  PF-06826647 was not mutagenic in bacterial revers e mutation 
assay s.  Although PF -06826647 was positi ve for micronuclei formation in vitro (through an 
aneugenic mechanism), it did not induce micronucle i invivo in rats at 500 mg/kg/day  
(250 mg/kg BID) (unbound Cmaxof 2110 ng/mL and AUC 24of 24,100 ng•h/mL ), the highest 
dose tested in the [ADDRESS_627009] 
dose tested of 500 mg/kg/day , demonstrating that PF -06826647 was not a phototoxicant, 
invivo.
Further details of the nonclinical safet y program are provided in the current investigator’s 
brochure.
2.2.2. Non-Clinical Pharmacokinetics and Metabolism
Single dose pharmacokinetic studies with PF -06826647 were conducted after oral and
intravenous (IV)administration to mice and rats.  PF -06826647 had moderate oral 
bioavailability  (26% to 51%) utilizing a spray ed-dried dispersion (SDD) formulation versus 
0.5% methy l cellulose (<1% to 12%).  After IV administration, PF -06826647 demonstrated a 
steady  state volume of distribution (Vss) of approximately  0.9 to 1.4 L/kg and a low plasma 
clearance (CL [10 to 18 mL/min/kg]), relative to mouse and rat liver blood flows.  Sy stemic 
exposures (maximum observed concentrations [C max] and are a under the concentration time 
curve [AUC]) of PF- 06826647 after repeat oral dosing in the pi[INVESTIGATOR_488018] (up to 500 mg/kg/day ) and monkey s (up to 
300mg/kg/day ) in a less than dose -proportional manner.  No sex-related differences in 
exposure and no accumulation of PF-06826647 were observed over the dosing period in 
either species.  In vitro, PF- 06826647 showed high apparent passive permeability  and may  be 
a substrate for P -glycoprotein (P -gp).  PF -06826647 b inding to plasma proteins ranged 
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 23between 62% to 82%, and PF-[ADDRESS_627010] for PF-06826647 is expected to be hepatic cytochrome P450 (CYP)-mediated metabolism by [CONTACT_097]1A2 (fraction metabolized [ f
m] = 0.53), CYP2D6 ( fm= 
0.26) and CYP3A ( fm= 0.21). PF-06826647 did not inhibit the major cytochrome CYP450 
or UDP- glucuronosyltransferase enzymes (UGT) (half maximal inhibitory concentration IC
50>25μM).  PF-06826647 induced CYP3A4 messenger Ribonucleic acid (mRNA) 
expression in 1 of 3 lots of hepatocytes ( ≥4.7-fold increase at ≥10μM), but no corresponding 
induction was seen in CYP3A4 enzymatic activity.  Induction of CYP1A2 enzyme activityoccurred in 2 lots of hepatocytes (approximately 2-fold at ≥10μM), and PF-06826647 did 
not induce CYP2B6 mRNA levels or enzymatic activity.  Based on its in vitro profile, the potential for PF-06826647 mediated CYP450 or UGT drug interactions is low at clinically relevant concentrations (C
max355 nM; C max,u 135 nM).
PF-06826647 showed little to no inhibition of the multidrug and toxin extrusion protein 
(MATE1), multidrug resistant protein 1 (MDR1), multidrug resistance-associated protein (MRP2), MRP3, sodium/taurocholate co-transporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1, OATP1B3 and organic cation transporter (OCT) 2.  However, PF-06826647 did inhibit MATE2K with an estimated IC
50value of 0.53 μM. 
2.2.3. Clinical Overview
The clinical development program for PF-06826647 is currently comprised of a
placebo-controlled Phase 1 study (C2501001).  In this study, six Single Ascending Dose (SAD) cohorts and five Multiple Ascending Dose (MAD) cohorts in healthy participants completed, with 69 healthy adult participants randomized and treated with PF-06826647 or placebo. The study also included one cohort of 6 healthy Japanese participants who received400 mg once daily (QD) and 2 cohorts of participants (total 40) with moderate to severe plaque psoriasis (First-in-Patient) who received 400 mg or 100 mg QD of PF-06826647 or placebo.  Psoriasis participants received active treatment with PF-06826647 (100 mg or 400 mg QD for 28 days) had clinically meaningful decreases in disease activity as measured by [CONTACT_488041] (PASI), the defined primary endpoint.
Safety, efficacy,  results from this study support further development 
of PF-06826647 in plaque psoriasis.  The Phase 1 study (C2501001) demonstrated an acceptable safety and pharmacokinetic profile at single doses of PF-06826647 ranging from 3 mg to 1600 mg in the SAD portion and ten-day dosing from 10 mg to 1200 mg daily in the MAD portion of the study.  Dose escalation stoppi[INVESTIGATOR_488019].  There were no clinically meaningful findings in vital signs, electrocardiograms (ECG), or potential Hy’s Law cases reported during this study.  In addition, there were no serious adverse events (including death) or Suspected, Unexpected, Serious Adverse Reactions (S[LOCATION_003]Rs) reported.  Based on preliminary review of treatment group data, all reported treatment emergent adverse events have been of mild intensity.
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 24Additionally, clinical benefit was observed in participant cohorts with plaque psoriasis as 
measured by [CONTACT_488042] a 28-day treatment period. In the participants completing 28 days of treatment with PF-06826647, the mean placebo-adjusted change from baseline PASI score at Week 4 was -14.02 (n=20) for the 400 mg QD cohort and -4.55 (n=15) for the 100 mg QD cohort. 
Please refer to Benefit/Risk Assessment Section 2.3 for more details on the clinical safety of
PF-06826647.
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 252.3. Benefit/Risk Assessment
PF-06826647 is expected to offer therapeutic benefit in the treatment of psoriasis.  More 
specifically, inhibition of IL-12 and IL-23 signaling mediated by [CONTACT_488043]2 inhibitory activity may provide a new and improved therapeutic benefit due to potential achievement of disease control, improvement of signs and symptoms, as well as improvements in quality of life.
Overall, the safety profile observed during the Phase 1 program for PF-06826647 appears to 
be acceptable at dosages up to 1200 mg daily administered orally over 10 days.  A longer dosing duration was explored in participants with moderate to severe psoriasis, who received the maximum PF-06826647 dose level of 400 mg and 100 mg daily for 28 days.  No serious or severe AEs were reported in the Phase 1 study. There was one psoriasis participant in the 400 mg cohort who met the protocol pre-specified stoppi[INVESTIGATOR_488020], although this participant had border line low lymphocytes at baseline.  As with 
other immunomodulators, the risk of infection is a potential concern due to the immunosuppressive effects of PF-06826647. 
In conclusion, the sponsor considers that the available information from the nonclinical and 
clinical data to date regarding PF-06826647 provide a favorable benefit-risk profile and supports its continued investigation as a potential treatment for plaque psoriasis. 
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events (AEs) of PF-06826647 may be found in the investigator’s brochure, which is the single reference safety document (SRSD) for this study. CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 263.OBJECTIVES , ESTIMANDS ,AND ENDPOINT S
3.1. Study Objectives, Endpoints and Estimand s--Investigational Treatment Period
Objectives Endpoints Estimands
Prim ary: Prim ary: Prim ary: 
To compare the efficacy of multiple 
dose levels of PF -06826647 versus 
placebo on the proportion of 
participants with moderate to severe 
plaque psoriasis achieving PASI 90.Proportion of 
participant s achieving 
PASI 90 (90% or 
greater improvement 
from Baseline) at 
Week 16.Estimand E1:
This estimand is intended to 
provide a population level estimate 
of the treatment effect of the IP 
alone on a binary responder 
endpoint; without the benefit of 
additional prohibited medications, 
regardless of participant ’s 
compliance with the IP dosing.
Population: Participants with 
moderate to severe plaque 
psoriasis as defined by [CONTACT_488038] .
Intercurrent Events: A) Pr ohibited 
medication –response will be 
considered negative for 
participants after receiving 
prohibited medication.   B) 
Withdraw al and all other events 
leading to missing data will be 
treated as in A).   C)Inadequate 
compliance –participants data w ill 
be us ed as recorded.
Population level summary: The 
difference in proportions between 
treated and placebo response rates .
Secondary: Secondary: Secondary: 
To compare the efficacy of multiple 
dose levels of PF -06826647 versus 
placebo on the proportion of 
participants with moderate to severe 
plaque psoriasis achieving PASI 75.Key secondary endpoint :
Proportion of 
participants achieving 
PASI 75 (75% or 
greater improvement 
from Baseline) at time 
points specified in the 
Schedule of Activities 
(SoA) .The binary secondary endpoints, 
when appropriate, w ill be analyzed 
descriptively and using estimand 
E1.
To compare the efficacy of multiple 
dose levels of PF -06826647 versus 
placebo on PGA score in participants Proportion of 
participants with PGA 
score clear (0) or 
PF-[ADDRESS_627011] clear (1) and 
≥2points improvement 
from baseline at time 
points specified in the 
SoA.
Proportion of 
participants with PGA 
score clear (0) or 
almost clear (1) at time 
points specified in the 
SoA.
To compare the efficacy of multiple 
dose levels of PF -06826647 versus 
placebo on the proportion of 
participants with moderate to severe 
plaque psoriasis achieving PASI 50 and 
PASI 100.Proportion of 
participants achieving 
PASI 50 (50% or 
greater improvement 
from Baseline), 
PASI 100 (100% from 
Baseline) at time 
points specified in the 
SoA.
To compare the efficacy of multiple 
dose levels of PF -06826647 versus 
placebo on PGA and PASI scores in 
participants with moderate to severe 
plaque psoriasis .Change from baseline 
and percent change 
from baseline in PASI 
scores at time points 
specified in the SoA.Estimand E2: 
This estimand is intended to 
provide a population level estimate 
of the treatment effect of the IP 
alone on a continuous endpoint; 
without the benefit of additional 
prohibited medications, regardless 
of participant ’s compliance with 
the IP dosing.
Population: Participants with 
moderate to severe plaque 
psoriasis as defined by [CONTACT_488044].
Intercurrent Events: A) Prohibited 
medication –all scores after 
participants receive prohibited 
medication will be omitted from 
the analysis and treated as missing 
scores.  Missing scores will be 
imputed based on the assumption 
that participants do not benefit 
from the IP treatment.   
B)Withdraw al and all other events 
leading to missing data will be 
treated similarly as in A).   
C)Inadequate compliance –
participants dat a will be used as 
recorded.
Population level summary: 
PF-[ADDRESS_627012] of multiple dose 
levels of PF-06822647 versus placebo 
in Peak-Pruritus Numerical Rating 
Scale score in participants with moderate to severe plaque psoriasis.•Absolute score and 
change from baseline 
in Peak-Pruritus 
Numerical Rating Scale score at time points specified in the SoA.
To assess the safety and tolerability of 
PF-06826647 in participants with moderate to severe plaque psoriasis.•Incidence and severity 
of adverse events, serious adverse events and withdrawals due to adverse events. 
•Change from baseline 
in clinical laboratory 
values (chemistry, hematology & lipi[INVESTIGATOR_805]).
•Incidence of clinically 
significant changes in 
ECG (heart rate, QT, 
QTc, PR and QRS intervals). 
•Change from baseline 
in vital signs (blood pressure, pulse rate and 
temperature 
measurements).There is no defined estimand for 
these endpoints and they will be analyzed using [COMPANY_007] data standards as applicable.
To compare the efficacy of multiple dose levels PF-06826647 versus placebo on measures of disease and 
symptom severity in participants with 
moderate to severe plaque psoriasis.•Absolute score and 
change from baseline Psoriasis Symptom 
Inventory at time 
points specified in the 
SoA
.This endpoint will be analyzed 
descriptively and using estimand E2 described above when appropriate.
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 29CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 30Study Objectives, Endpoints and Estimands -- Extension Treatment Period
Objectives Endpoints Estimands
Primary: Primary: Primary: 
To assess the safety and tolerability of PF-06826647 in participants with 
moderate to severe plaque psoriasis.•Incidence and severity of 
adverse events, serious 
adverse events and 
withdrawals due to adverse events. 
•Change from baseline in 
clinical laboratory values 
(chemistry, hematology 
& lipi[INVESTIGATOR_805]).
•Incidence of clinically
significant changes in ECG (heart rate, QT, QTc, PR and QRS 
intervals). 
•Change from baseline in 
vital signs (blood pressure, pulse rate and temperature 
measurements).Not Applicable, will be analyzed 
descriptively and according to the 
[COMPANY_007] standard.
CCICCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 314. STUDY DESIGN
4.1. Overall Design
This is a Phase 2b, randomized, double blind, placebo controlled, parallel group, multicenter 
study in participants with moderate to severe plaque psoriasis.  After a screening period of - up to 6 weeks, eligible participants will be randomized in a 2:1:1:2:2 ratio such that participants will receive placebo or either one of four PF-06826647 daily dose levels (50 mg, 100 mg, 200 mg or 400 mg) every day during the Investigational Treatment Period for 16 weeks in a blinded fashion.  All participants completing the 16-week Investigational Period will continue to a 24-week non-placebo-controlled Extension Treatment Period with double blind oral daily treatment, if per the Investigator judgment the participant is compliant with study procedures and continued participation presents no safety risks.  The participants continuing into the Extension Treatment Period that were originally randomized to the CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE] mg and 400 mg treatment groups will continue their respective doses, while those 
randomized to one of the other treatment groups (including placebo) will be randomly assigned (at study baseline) to receive either [ADDRESS_627013] an Early Termination visit and will not be eligible for the Extension Period.
Approximately 160 participants (40 participants in each of the following arms: placebo, 
200 mg, and 400 mg; and 20 participants in each of the following arms: 50 mg and 100 mg) will be randomly assigned to a treatment group in order to ensure a minimum of 128 evaluable participants completing Week 16 (assuming a 20% dropout rate).
The total duration of study participation will be approximately [ADDRESS_627014] (IP) treatment, the participant will 
proceed with the Early Termination (ET) and Follow Up visits per Schedule of Activities . 
4.2. Scientific Rationale for Study Design
This study is being conducted to provide data on efficacy, safety, tolerability,  
 of PF-06826647 in the oral treatment of moderate to severe plaque 
psoriasis.  The chronic toxicology package supports the planned study duration.
The treatment duration of 16 weeks in this Phase 2 study (C2501004) will allow for further 
exploration of the clinical safety and efficacy that was observed in the 4-week Phase 1(C2501001) study in a small (n=40) number of psoriasis participants.  The PASI 90 score at Week 16 will be assessed as the study’s primary endpoint.  The 50 mg once daily (QD) PF-06826647 dose will be explored in order to identify the minimal clinically efficacious dose after 16 weeks of treatment.  In order to further characterize the dose-response relationship, this study will explore 100 mg, 200 mg and 400 mg for 16 weeks during the Investigational Treatment Period of the study.  Based on the exposure-response modeling with the PASI data observed up to Week 4, the projected PASI 90 response rates at 200 mg and 400 mg are 47% and 83% at Week 16 respectively, while 50 mg and 100 mg are expected to provide <15% PASI [ADDRESS_627015] a smaller allocation of participants as compared to the other treatment groups.  Furthermore, participants randomized to placebo, 50 mg, and 100 mg 
doses during the Investigational Treatment Period will receive either 200 mg or 400 mg
during the Extension Study Period in order to evaluate additional safety, tolerability, and durability of response to PF-06826647 at expected clinically efficacious doses.
Since PF-06826647 is metabolized primarily by [CONTACT_097]1A2, CYP3A4 and CYP2D6, the strong 
and moderate inducers and inhibitors of these drug metabolizing enzymes are prohibited.  Dofetilide being a MATE substrate is also prohibited because PF-06826647 is a MATE2K substrate and can potentially increase exposure. CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 33The requirement for female participants using hormonal contraceptives to use an additional 
barrier method may be removed if supported by [CONTACT_488045] (Study C2501005).
  
Patient reported outcomes will evaluate changes in psoriasis symptoms and health-related 
quality of life.  These utility scores will be further utilized for development of an early cost-effectiveness model. 
The potential risk of exposure to PF-06826647 in a sexual partner of a male participant in 
this study via ejaculate is low, and therefore no barrier contraception (condom) use in male participants is warranted.  The calculated safety margin is ≥100-fold between the estimated 
partner exposure due to seminal transfer and the no-observed-adverse-effect level (NOAEL) for serious manifestations of developmental toxicity in nonclinical studies.  The safety margin of 100-fold is based on applying a 10-fold safety factor for interspecies extrapolation and a 10-fold safety factor for susceptible populations.
 
 
4.3. Justification for Dose
Dose selection for this study was based on expected average inhibition of IL-12, IL-23, and 
IFNαas well as projected in vivo efficacy observed in psoriasis participants without 
significant JAK2 inhibition.  Four dosing (50 mg QD, 100 mg QD, 200 mg QD and 
400 mg QD) regimens of PF-06826647 and placebo were selected to explore the dose range in moderate to severe psoriasis participants given the practical considerations.
 
 
 
 
 CCI
CCI
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 34Based on the exposure-response modeling with the PASI data observed up to Week 4, the 
projected PASI 90 response rates of 50 mg, 100 mg, 200 mg, and 400 mg were 3%, 13%, 47%, and 83% at Week 16, respectively.  However, there is uncertainty in the extrapolation of response from Week 4 to Week 16.  Although the projected PASI 90 response rates of 50 mg QD is low, the projected average inhibition (Table 3) based on in vitro IC
50value 
determined by [CONTACT_488046] (pSTAT)modulation in human whole blood, red blood cell (RBC) partition ratio of 1.4 and assuming 
Hill coefficient of 1, the average daily inhibition of IL-12, IL-23, IFN αis approximately 
82%, 69% and 79%, respectively.  Considering both the projected PASI [ADDRESS_627016] dose of 400 mg QD was selected based on practical considerations of daily tabletburden to participants and projected high degree of inhibition (>90%) of IL-12, IL-23 and 
IFNα(Table 3) at steady state. 
Additionally, based on data observed to date in both healthy and psoriasis participants, these 
doses are expected to be safe and well tolerated.  All the adverse events (AEs) observed in healthy participants up to 1200 mg QD for 10 days and psoriasis participants up to 400 mg QD for 28 days were mild in nature.  Although, the projected average inhibition of erythropoietin (EPO) (Table 3) was 67% and a transient decrease in reticulocyte was observed in psoriasis participants at [ADDRESS_627017] dose of 400 mg QD at steady state is expected to provide 
margins of about 2-fold for C maxand about 3-fold for AUC relative to the total exposure
(NOAEL) in the monkey 9-month chronic toxicity study.
In Study C2501001, the 6 β-hydroxycortiso l/cortisol ratio in urine was evaluated as a marker 
of CYP3A induction but there were no differences between PF-06826647 treated versus 
placebo participants. Thus, the risk of induction of metabolic pathways is considered low.
Ethinylestradiol (EE) containing oral contraceptives (OC) has been shown to increase the 
exposure of CYP1A2 substrates such as caffeine. Based on in vitro experiments, the major human clearance pathway for PF-06826647 is expected to be hepatic CYP-mediated metabolism by [CONTACT_097]1A2, CYP2D6 and CYP3A out of which CYP1A2 is expected to contribute ~53%. Therefore, the highest expected increase in exposure of PF-06826647 based on CYP1A2 inhibition is ~2-fold. The predicted exposure margins for Total C
maxand 
Total AUC with ~2-fold increase in exposure at the highest dose of 400 mg QD is approximately 0.94 and 1.67, respectively.
With maximum expected increase in exposure of PF-06826647 due to interaction with EE, 
the maximum expected erythropoietin (EPO) inhibition at 400 mg QD will be approximately 80%. Reticulocyte count and hemoglobin level will be monitored on a regular basis in the study for safety  for EPO inhibition. 
The Phase 1 study (C2501001) demonstrated an acceptable safety profile at single doses of 
PF-06826647 ranging from 3 mg to 1600 mg in the single ascending portion and ten-day doses from 10 mg to 1200 mg daily in the multiple ascending portion of the study.  Dose escalation stoppi[INVESTIGATOR_488019].  There were no clinically meaningful findings in vital signs, ECGs, or potential Hy’s Law cases reported during this study.  In addition, there were no serious AEs (including death) or suspected, unexpected, serious adverse reactions (S[LOCATION_003]Rs) reported.  All reported Treatment Emergent Adverse Events (TEAEs) were of mild intensity.
The 200 mg and 400 mg doses were selected for the Extension Treatment Period due to the 
higher projected PASI 90 response rates at these doses.  Based on the exposure-response modeling with the PASI data observed up to Week 4, the projected PASI 90 response rates at 200 mg and 400 mg are 47% and 83% at Week 16 respectively, while 50 mg and 100 mg are expected to provide <15% PASI [ADDRESS_627018] completed the study if he/she has completed all phases of 
the study including the last visit or the last scheduled procedure shown in the Schedule of 
Activities .
The end of the study is defined as the date of the last scheduled procedure shown in the 
Schedule of Activities for the last participant in the trial globally.CCI
PF-[ADDRESS_627019] participants for whom participation in the study is considered appropriate.  All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all the following criteria apply:
Age and Sex:
1. Male or female participants between the ages of 18 (or the minimum country-specific 
age of consent if >18) and 75 years, inclusive, at Screening.
•Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2 ) participants.
Type of Participant and Disease Characteristics:
2. Participants who are willing and able to comply with all scheduled visits, treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.
3. Participants with a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 
6 months prior to Baseline/Day 1 (prior to first dose of study drug).
4. Have a PASI score of 12 or greater AND a Physician Global Assessment score of 
3 (“moderate”) or 4 (“severe”) at Baseline/Day 1 (prior to first dose of study drug).
 
Weight:
6. Body weight must be >40 kg.
Informed Consent:
7. Capable of giving signed informed consent as described in Appendix 1 , which
includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.
8. Must discontinue systemic, topi[INVESTIGATOR_199]/or phototherapy therapi[INVESTIGATOR_014] (eg, ultraviolet B 
(UVB) or photochemotherapy (PUVA)) for the treatment of psoriasis per timing criteria described in Section 5.2 .CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 375.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Currently  have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular 
psoriasis, except for nail psoriasis which is allowed.
2.Evidence of other skin conditions (eg, eczema) at the time of screening or baseline 
visit that would interfere with the evaluation of psoriasis.
3.Current drug-induced psoriasis, eg, a new onset of psoriasis or an exacerbation of 
psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium.
4.If receiving non-prohibited concomitant medications for an y reason, must be on a 
stable regimen, which is defined as not starting a new drug or changing dosage within 
7days or 5 half-lives (whichever is longer) prior to first dose of study  drug.
5.Any psychiatric condition including recent (within the past y ear)or active suicidal 
ideation or behavior that meets any  of the following criteria:
a.Suicidal ideation associated with actual intent and a method or plan in the past 
year: “Yes” answers on it ems 4 or 5 of the Columbia suicide severit y rating scale 
(C-SSRS) ( 10.9).
b.Previous history  of suicidal behaviors in the past 5 years: “Yes” answer (for 
events that occurred in the past 5 years) to an y of the suicidal behavior items of 
the C -SSRS. 
c.In the opi[INVESTIGATOR_94367] (or designee) exclusion is required.
6.Have an y condition possibly  affecting oral drug absorption, eg, gastrect omy, 
clinically  significant diabetic gastroenteropathy , or certain t ypes of bariatric surgery  
such as gastric b ypass.  Procedures such as gastric banding, that simply  divide the 
stomach into separate chambers, are NOT exclusionary .
7.Have current or recent (within the past y ear) history  of severe, progressive, or 
uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, 
pulmonary , cardiovascular, or neurological disease.
8.History of any  lymphoproliferative disorder (such as Epstein -Barr virus
[EBV] -related l ymphoproliferative disorder, history  of ly mphoma, leukemia, or signs 
and sy mptoms suggestive of current l ymphatic disease.
9.History (single epi[INVESTIGATOR_1865]) of disseminated herpes zoster or disseminated herpes 
simplex, or a recurrent (more than one epi[INVESTIGATOR_44715]) localized, dermatomal herpes 
zoster.
PF-[ADDRESS_627020] dose of study  drug.
11.Infected with My cobacterium tuberculosis (TB) (see Section [IP_ADDRESS] ).
12.Have known immunodeficiency  disorder or a first -degree relative with a hereditary  
immunodeficiency .
13.History  of recurrent (≥2) venous thrombosis or any  arterial thromboembolism or 
known bloo d clotting disorders. 
14.History  of acute coronary  syndrome (eg, m yocardial infarction, unstable angina 
pectoris) and an y history of cerebrovascular disease within [ADDRESS_627021] undergone significant trauma or major surgery  within 1 month prior to 
Screening or plan to undergo surgery  during treatment period.
17. O ther acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or active suicidal ideation or behavior or laboratory  abnormality  that may  
increase the risk associated with study  participation or investigational product 
administration or may  interfere with the interpretation of study  results and, in the 
judgment of the investigator, would make the participant inappropriate for entry  into 
this study .  For an y reason i n the opi[INVESTIGATOR_26335], the 
participant is inappropriate for entry  into this study .
Prior/Concomitant Therapy:
18. P lanned initiation of, or changes to, concomitant medication that could affect 
psoriasis (eg, beta blockers, calcium channel blockers, antimalarial drugs or lithium) 
are to occur withi n 2weeks prior to randomization and/or during the study .
19.Are taking or require oral or injectable (eg, intraarticular, intramuscular or 
intravenous) corticosteroids for an y condition. (Must be discontinued for at least 
4weeks prior to first dose of stud y drug ).
20.Have been vaccinated with live or attenuated live vaccine within the [ADDRESS_627022] do seof study  drug.  (For further 
information regarding avoidance of household contacts who may  be vaccinated see 
Section 5.3.2 ).
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 3921.Require treatment with prohibited concomitant medications(s) ( see Section 6.5) or
have received a prohibited concomitant medication/dietary  supplement within 7 days 
or 5half-lives (whichever is longer) prior to the first dose of study  drug. Details 
include specific discontinuation recommendations and, additional detai ls are found in 
Appendix 8.
22.Previous administration with an investigational drug within 30days (or as determined 
by [CONTACT_19970]) or 5half-lives preceding the first dose of investigational 
product used in this study (whichever is longer).
Diagnost ic Assessments:
23.Known history  of incompletely  treated h epatitis B or C, or human immunodeficiency  
virus (HIV) based on documented history  with positive serological test, or positive 
HIV serological test at screening.
Participants who are hepatitis C antibody  (HCVAb) positive require further 
testing with Hepatitis C virus (HCV) ribonucleic acid (RNA) Poly merase 
chain reaction (PCR) may be eligible if HCV RNA PCR is negative .
Participants who are hepatitis B surface anti gen (HBsAg) negative and 
hepatitis B core antibod y (HBcAb) positive will be reflex tested for 
Hepatitis B Surface Antibody  (HBsAb). If HBsAb is positive, participant 
may be eligible.  If HBsAb is negative, the participant is not eligible. This 
reflex test applies to all countries except Japan. 
Participants who are negative for all three serology tests may  be eligible. 
Participants who are HBsAg positive are not eligible. 
In Japan ONLY , allparticipants will undergo testing for all three tests HBsAg, 
HBcAb, and HBsAb during Screening. 
Participants who have negative HBsAg, positive HBcAb, and negative 
HBsAb are not eligible. 
Participants who have negative HBsAg, negative HBcAb and positive HBsAb 
and provide a documentation of prior Hepatitis B Virus (HB V) vaccination 
may be eligible and will not require HBV DNA monitoring during the study . 
Participants who have negative HBsAg, negative HBcAb and positive HBsAb 
without documentation of prior HBV vaccination, and who have negative 
HBsAg, positive HBcAb and positive HBsAb are required to undergo HBV 
DNA reflex testing.
Participants with detectable HBV DNA are not eligible.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 40Participants without detectable HBV DNA may  be eligible. If enrolled, 
HBV DNA will be assessed at Weeks 12 (Investigational Treatment 
Period), Weeks 24, 36 (Extension Treatment Period) and ET (if 
applicable).
24.Screening or b aseline standard 12- lead electrocardiogram (ECG) that demonstrates 
clinically  relevant abnormalities that may  affect participant safety  or interpretation of 
study  result s (eg, baseline corrected QT [QTc] interval >450 millisecond ( msec ),
complete left bundle branch block [LBBB], signs of an acute or indeterminate -age 
myocardial infarction, ST -T interval changes suggestive of my ocardial ischemia, 
second -or third -degree at rioventricular [AV] block, or serious brad yarrhythmias or 
tachyarrh ythmias).  If the baseline uncorrected QT interval is >450 msec, this interval 
should be rate -corrected using the Fridericia method and the resulting corrected QT 
interval by  [CONTACT_6550] (QTcF ) should be used for decision making and reporting.  If 
QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 
2 more times and the average of the 3 QTc or QRS values should be used to 
determine the participant’s eligibility .  Comput er-interpreted ECGs should be over 
read by a ph ysician experienced in reading ECGs before excluding participants.
25.Participants with ANY of the following abnormalities in clinical laboratory  tests at 
screening, as assessed b y the study -specific laboratory  and confirmed by  a single 
repeat, if deemed necessary :
Hemoglobin <11.0 g/dL or hematocrit <30% (<0.30 v/v);
White blood cell count <3.0 x 109/L(<3000 mm3); 
Absolute ly mphocy tecount of <1.0 x 109/L(<1000 /mm3);
Absolute neutrophil count of <1.5 x 109/L (<1500/mm3);
Platelet count <100 x 109/L (<100,000/mm3);
eGFR (estimated glomerular filtration rate) <60mL/min/1.73 m2using serum 
creati nine based on the Chronic Kidney  Disease Epi[INVESTIGATOR_8849] 
(CKD EPI ) calculation ;
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values 
>2 times the upper limit of normal (ULN);
Total bilirubin ≥1.[ADDRESS_627023]; participants with a history  of Gilbert's 
syndrome may  have a direct bilirubin measured and would be elig ible for this 
study  provided the direct bilirubin is <UL N.
PF-[ADDRESS_627024] interpretation of study  data or the 
participan t’s participation in th e study .
Other Exclusions:
26. Investigat orsite staff members directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by  [CONTACT_093] , or 
Sponsor employ ees, including their family  members, directl y involved in the conduct 
of the study .
27.Have a history  of alcohol or substance abuse, unless in full remission for greater than 
[ADDRESS_627025] be made aware of the following life 
style guidelines and restrictions that apply  during and after the study  period.  Details of these 
life sty le guidelines are provided in sections as noted.
On appropriate study  visit day s, compl y with fasting requirement (water only ) for at 
least 8 hours prior to the visit, as indicated in the Schedule of Activities.
On study  visit day s, do not smoke or ingest caffeine (eg, tea, coffee, some soft 
drinks/colas/energy  drinks and power bars) during the 30 minutes prior to blood 
pressure and pulse rate measurements.
Only on study  visit day s, do not take the dose of study  drug until instructed to do so 
by [CONTACT_488047].
On study  visit day s, show ering or bathing is permitted prior to attending the study  
visit, but do not moisturize.
On study  visit day s, take prescribed permitted concomitant medication, as needed, 
prior to the study  visit, if it can be administered with water onl y.  Prescribed 
perm itted concomitant medications that must be taken with food or after meals should 
not be taken until after the visit procedures have been completed.
Contact [CONTACT_488048] y changes or additions to 
concomitant medications.
As nee ded, participants may use the treatments listed as permitted in Section 6.5 for
the specified bod y sites described.  On clinic visit days, do not use an y of these 
treatments until after the clinic visit is completed.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 42Abstain from strenuous exercise (eg, heav y lifting , weight training, calisthenics, and 
aerobics) for at least 48 hours prior to each blood collection for clinical laboratory  
tests.  Walking at a normal pace is permitted.
Avoid prolonged exposure to the sun and avoid use of tanning booths or other 
ultravio let light sources during the stud y.
Herbal supplements must be discontinued [ADDRESS_627026] dose of study  
medication   It is recommended that participants avoid excessive consumption of 
grapefruit or grapefruit juice or citrus fruits eg, Seville oranges orpomelos not to 
exceed 8 ounces (~240 mL) total in a day  while in the study .
5.3.1. Contraception 
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4 ) and will confirm that the participant has been instructed in its 
consistent and correct use.  At time points indicated in the Schedule of Activities (SoA) , the 
investigator or designee will inform the participant of the need to use highly  effective 
contraception consistently and correctly and document the conversation and the participant’s 
affirmation in the participant’s chart (participants need to affirm their cons istent and correct 
use of at least 1 or 2of the selected methods of contraception).  In addition, the investigator 
or designee will instruct the participant to call immediately  if the selected contraception 
method is discontinued or if pregnancy  is known or suspected in the participant or partner.
Female participants using hormonal contraceptives are required to use an additional 
acceptable barrier method listed in Contraception (Section 10.4.4) during the study  and until 
[ADDRESS_627027] 
been vaccinated with live vaccine components should be avoided in the same period.  This is 
due to the potential for virus to be shed in bodily  fluids ( including stool ) following 
vaccination with live component vaccines, leading to a potential risk that the virus may  be 
transmitted.
Such vaccines include: FluMist®(intranasal influenza vaccine), attenuated rotavirus vaccine, 
varicella (chickenpox) vaccine, attenuated t ypho id fever vaccine, oral polio vaccine, measles, 
mumps, rubella (MMR) vaccine and vaccinia (smallpox) vaccine. 
PF-[ADDRESS_627028] y with fasting requirement (water only ) for at 
least [ADDRESS_627029] caffeine (eg, tea, coffee, some soft 
drinks/colas/energy  drinks and power bars) during the 30 minutes prior to blood 
pressure and pulse (heart) rate measurements.
3. O nly on study  visit day s, do not take the dose of study  drug until instructed to do so 
by [CONTACT_488049] y site staff while at the study  site.
4.On study  visit day s, showering or bathing is permitted prior to attending the study  
visit, but do not moisturize.
5.On study  visit day s, take prescribed permitted concomitant medication, as needed,
prior to the study  visit, if it can be administered with water onl y.  Prescribed 
permitted concomitant medications that must be taken with food or after meals should 
not be taken until after the visit procedures have been completed.
6.Contact [CONTACT_488048] y changes or additions to 
concomitant medications.
7.As needed, participants may use the treatments listed as permitted in Section 6.5for
the specified bod y sites described.  On clinic visit days, do not use an y of these 
treatments until after the clinic visit is completed.
8.Abstain from strenuous exercise (eg, heav y lifting, weight training, calisthenics, and
aerobics) for at least [ADDRESS_627030] udy 
medication. I t is recommended that participants avoid excessive consumption of 
grapefruit or grapefruit juice or citrus fruits eg, Seville oranges or pomelos 
exceeding 8 ounces (~240 mL ) total in a day  while in the study .
PF-[ADDRESS_627031] . Screen failure data are 
collected and remain as source and are not reported to the clinical database.   A minimal set of 
screen failure information isrequired to ensure transparent reporting of screen failure 
participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory  authorit ies.  Minimal information 
includes demograph y, screen failure details, eligibility  criteria, and any  serious adverse event 
(SAE).   Individuals who do not meet the criteria for participation in this study  (screen failure) 
may be rescreened once. 
Re-screened participants will be re-consent ed. All screening assessme nts must be repeated 
during re -screening, with the exception of chest radiograph, HIV, Hepatitis and TB testing, 
provided re -screening is done within 3 months of screening .
6.STUDY INTERVENTION
Study intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
For the purposes of this protocol, the term investigat ional product m ay be used 
synony mously  with study  intervention .
6.1.Study Intervention(s) Administered
Blinded PF -06826647 and matching placebo will be provided as tablets for oral 
administration. PF-06826647 will be provided in dosage strengths of 100 mgand25mg
tablet s.  PF -06826647 and matching placebo will be supplied in blister cards and labeled 
according to local regulatory  requirements.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 45Intervention Name [INVESTIGATOR_16335]-06826647 PF-06826647 PF-06826647 PF-06826647 Placebo
ARM Nam e PF-06826647 
50mgPF-06826647 
100 mgPF-06826647 
200 mgPF-06826647 
400 mgPlacebo
Type Drug Drug Drug Drug Drug
Dose Formulation Tablet Tablet Tablet Tablet Tablet
Dosage Level(s) 50 mg QD 100 mg QD 200 mg QD 400 mg QD Placebo
Number and Type 
of Tablets During 
Investigational 
Treat ment Period, 
Day 0 to Week 16 
(Number of 
Tablets)2 x 25 mg active, 
and
4 x 100 mg size 
placebo2 x 25 mg size 
placebo, and
1 x 100 mg 
active, and
3 x 100 mg size 
placebo2 x 25 mg size 
placebo, and
2 x 100 mg 
active, and
2 x 100 mg si ze 
placebo2 x 25 mg size 
placebo, and
4 x 100 mg 
active2 x 25 mg size 
placebo, and
4 x 100 mg size 
placebo
Number and Type 
of Tablets During 
Extension 
Treat ment Period, 
Week 16 to Week 
40 (Number of 
Tablets)[ADDRESS_627032] 
(IMP) and 
Noninvestigational 
Medicinal Product 
(NIMP)IMP IMP IMP IMP N/A
Sourcing Provided 
centrally by [CONTACT_488050].Provided 
centrally by [CONTACT_488050].Provided 
centrally by [CONTACT_488050].Provided 
centrally by [CONTACT_488050].Provided 
centrally by [CONTACT_488051].
Packaging and 
LabelingStudy 
intervention will 
be provided as 
tablets in blinded 
blister cards.  
Each blister card 
will be labeled as 
required per 
country 
requirement.Study 
intervention will 
be provided as 
tablets in blinded 
blister cards.  
Each blister card 
will be labeled as 
requi red per 
country 
requirement.Study 
intervention will 
be provided as 
tablets in blinded 
blister cards.  
Each blister card 
will be labeled as 
required per 
country 
requirement.Study 
intervention will 
be provided as 
tablets in blinded 
blister cards.  
Each b lister card 
will be labeled as 
required per 
country 
requirement.Study 
intervention will 
be provided as 
tablets in 
blinded blister 
cards.  Each 
blister card will 
be labeled as 
required per 
country 
requirement.
Participants will receive blinded labeled supplies throughout the stud y.  To accomplish this, 
all participants will take a total of six tablets per day  during the Investigational Treatment 
Period, and four tablets per day  during the Extension Treatment Period.
PF-[ADDRESS_627033] (IP) whole and will not manipulate or 
chew the IPprior to swallowing.  Participants will administer IP as outpatients , except on 
study  visit days.  Onstudy  visit day s, participants should not take their dose of study  drug 
until instructed to do so by [CONTACT_488052].
Blinded PF -[ADDRESS_627034] manual and/or other vehicle(s).   Sites are responsible for 
communicating this information to participants; and site staff should review the dosing 
instructions with participants at every  study  visit.
Participants should take the IPorally once daily during the Investigational Treat ment Period 
andthe Extension Treatment Period of the study . 
A temporary  hold on dosing of the investigational product during the study for an individual 
participant for up to a maximum of 7consecutive day s is allowed once from Day 1 to 
Day 113, if the principal investigator ( PI)deems it necessary  because of infections (eg, upper 
respi[INVESTIGATOR_23739], urinary  tract infection), gastrointestinal ( GI) disorders (eg, diarrhea, 
nausea, vomiting) or hematological abnormalities.   Any temporary  hold on dosing of the 
investigational product during the stud y should be recorded in the case rep ort form ( CRF ).
It is recommended that the tablets be swallowed whole with ambient temperature water to a 
total volume of approximately  240 mL, and not to manipulate or chew the medication prior 
to swallowing; and it is recommended to be taken with food .  On study  visit day s, 
participants are to be instructed to refrain from dosing at home and are to take the dose in the 
clinic from their current blister card and the dose from the newl y dispensed blister card will 
be taken on the next day  at home.
If a do se is missed and the interval to the next dose is less than 8 hours, the missed dose 
should not be administered.
6.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained d uring transit for all study  interventions received and any  
discrepancies are reported and resolved before use of the study  intervention, as 
applicable for temperature -monitored shipments. 
PF-[ADDRESS_627035] be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
condi tions with access limited to the investigator and authorized site staff.  At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request.  Data for nonworking days must 
indicate the minimum and maximum temperature since previousl y documented for all 
site storage locations upon return to business.
3.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reco nciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records).  All study  
interventions will be accounted for using an investigational product accountability  
form/record.   The participant will be asked to bring all dispens ed investigational 
product (including empt y, partially used and unused blister packs) and the dosing 
diary  to the clinic at every  visit.  Detailed drug accountability  records will be 
maintained by  [CONTACT_488053] .
4. Further guidance and info rmation for the final disposition of unused study  
interventions are provided in the investigational product ( IP)manual.
5.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_177264]. 
6.Study  interventions should be stored in their original containers and in accordance 
with the labels. 
7.Site staff will instruct participants on the proper storage requirements for take -home 
study  intervention. 
8.Any excursions from the study  intervention label storage conditions should be 
reported to the sponsor upon discovery  along with any  actions taken.  The site should 
activel y pursue options for returning the stud y intervention to the storage conditions 
described in the labeling, as soon as possible.  On ce an excursion is identified, the 
study  intervention must be quarantined and not used until the sponsor provides 
permission to use the study  intervention.  I t will not be considered a protocol 
deviation if the sponsor approves the use of the study  interve ntion after the 
temperature excursion.   Use of the stud y intervention prior to the sponsor’s approval 
will be considered a protocol deviation.  Specific details regarding the definition of an 
excursion and information the site should report for each excurs ion will be provided 
to the site in the I P manual.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 489.The sponsor or designee will provide guidance on the destruction of unused study  
intervention (eg, at the site).  If destruction is authorized to take place at the 
investigator site, the investigator must ensure that the materials are destro yed in 
compliance with applicable environmental regulations, institutional policy , and any  
special instructions provided by [CONTACT_456] , and all destruction must be adequatel y 
documented.
Additional details about accoun tability , storage, destruction, and excursion reporting can be 
found in the IP manual.
6.2.1. Preparation and Dispensing
The investigational product will be dispensed using an interactive response technology  (IRT)
drug management system at each visit per SoA.  A qualified staff member will dispense the 
investigational product via unique container numbers in the blister cards provided, in 
quantities appropriate for the study  visit schedule.  The participant/caregiver should be 
instructed to maintain the product in the blister cards provided throughout the course of 
dosing and return the blister cards (including empty , partially  used and unused blister packs) 
to the site at the next study visit.
6.2.2. Investigational Product Account ability 
The investigator site must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product supplies.  All investigational products will be 
accounted for using a drug accountabilit y form/record.  All blister cards of investigational 
product must be returned to the investigator b y the participant at every visit and at the end of 
the trial.
The participant will be asked to bring all dispensed investigational product (including empt y, 
partially  used a nd unused blister packs) and the dosing diary  to the clinic at every  visit.  
Detailed drug accountability  records will be maintained by  [CONTACT_488053].
The original investigational product accountability log, or equivalent document, must be 
accuratel y completed, signed by [CONTACT_737], and retained at the stud y site (with a cop y 
supplied to the s ponsor) when the stud y is complete.
6.2.3. Destruction of Investigational Product Supplies 
The investigator will keep the entire investigational pro duct returned b y the participants until 
destruction is authorized. 
The sponsor or designee will provide guidance on the destruction of unused study  
intervention (eg, at the site).  If destruction is authorized to take place at the investigator site, 
the investigator must ensure that the materials are destroyed in compliance with applicable 
environmental regulations, institutional policy , and any  special instructions provided by  [CONTACT_103] , and all destruction must be adequatel y documented.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 49Further guidanc e and information for the final disposition of unused study  interventions are 
provided in the I P manual.
6.3.Measures to Minimize Bias: Randomization and Blinding
Allocation to treatment will occur via an Interactive Response Technology (I RT) sy stem.  
The sy stem will be programmed with blind -breaking instructions.  Refer to subsections 6.3.[ADDRESS_627036]
Allocation of participants to treatment groups will proceed through the use of an interactive 
response technology  (IRT) sy stem (interactive Web -based response [ IWR]).  The site 
personnel (stud y coordinator or specified designee) will be required to enter or select 
information including but not limited to the user’s identification (ID) and password, the 
protocol number, and the participant number.  The site personnel will then be provided with a 
treatment assignment, randomization number, and dispensable unit (DU) or container number 
when investigational product is being supplied via the I RT s ystem.  The IRT sy stem will 
provide a confirmation report containing the participant number, randomization number, and
DU or container number assigned.  The confirmation report must be stored in the site’s files. 
Investigational product will be dispensed at the study  visits summarized in the SoA. 
Returned investigational product must not be redispensed to the participants.
The study -specific I RT reference manual and I P manual will provide the contact [CONTACT_19974] s ystem.
6.3.2. Breaking the Blind 
At the initiation of the study , the investigator si te will be instructed on the method for 
breaking the blind.  The method will be an electronic process.  The IRT will be programmed 
with blind -breaking instructions. In case of an emergency , the investigator has the sole 
responsibility  for determining if unblinding of a participant’s treatment assignment is 
warranted. Participant safety  must alway s be the first consideration in making such a 
determination.   If the investigator decides that unblinding is warranted, the investigator 
should make every  effort to contact [CONTACT_1152] a participant’s treatment 
assignment unless this could delay  further management of the participant.  However, 
discussion with the s ponsor in advance of unblinding is not required. If a participant’s 
treatment ass ignment is unblinded, the sponsor must be notified within [ADDRESS_627037] be recorded in the 
source documentation and case report form (CRF ).  Any cases of unblinding will be 
documente din the clinical study  report.  The study -specific I RT reference manual and IP 
manual will provide the contact [CONTACT_310793] I RT s ystem.
PF-[ADDRESS_627038] at home; compliance will be captured 
daily  by [CONTACT_50591] a Dosing Diary  and instructions provided by  [CONTACT_779].  The 
participant will be instructed to complete the Dosing Diary  (each time investigational product 
is provided in the clinic or at h ome) starting with the first dose provided in the clinic on 
Day 1,then dail y through Week [ADDRESS_627039] will be assessed at each visit.  If a visit is 
missed consult the Medical Monitor.  Comp liance will be assessed b y review of the 
participant -completed Dosing Diary  and source documents will be placed in the participant’s 
study  file.  Participants will be instructed to bring the Dosing Diary  and all dispensed 
inves tigational product supplies in the original packaging (used as well as unused) to every  
study  visit.
Non- compliance is defined as less than 80% or more tha n 120% of I P dosing as directed b y 
the dosing instructions.   The investigator and the sponsor have the discretion to withdraw an y 
participant from the study  for reasons of non- compliance with the dosing regimen.  
Investigators should indicate on the appropriate CRF page noncompliance with study  
intervention and provide an explanation.  I nventory  control of all investigational products 
must be rigorousl y maintained throughout the duration of the study  until all medication has 
been accounted for and/or returned to the sponsor.  Any discrepancies noted between drug 
dispensing records and the drug inventory  must be reported to the sponsor.
6.5. Concomitant Therapy
Permitted Concomitant Medication
Body Region Perm itted Topi[INVESTIGATOR_488021], soles, face, and intertriginous areas Low or least potent (Class 6 or 7) topi[INVESTIGATOR_153826] ≤1% and hydrocortisone acetate ≤1% are the 
only topi[INVESTIGATOR_153827] -medicated emollient, Cetaphilmoisturizing 
cream
Prohibited Concomitant Medications
1.The following h ydrocortisones are NOT permitted:
Hydrocortisone 17 butyrate.
Hydrocortisone valerate.
Hydrocortisone/hy drocortisone acetate with concentration higher than 1%.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 512.If received an y of the following treatment regimens, for an y reason, are eligible 
providing the following minimum washout criteria are observed:
Must be discontinued for at least 12weeks prior to first dose of study  drug:
a.Any investigational or experimental therapy  or procedure for psoriasis, 
psoriatic arthritis or rheumatoid arthritis;
b.efalizumab (Raptiva®), secukinumab (Cosent yx) or I xekizumab (Taltz) or 
other anti -IL-17, tofacitinib (Xeljanz) or treatment with apremilast (Otezla).
Must be discontinued forat least 10weeks prior to first dose of study  drug:
a.Adalimumab (Humira®);
b.Certolizumab pegol (Cimzia®);
c.Infliximab (Remicade®);
d. Alefacept (Amevive®).
Must be discontinued for at least 4weeks prior to first dose of study  drug:
a.Etanercept (Enbrel®);
b.Systemic treatments other than biologics that could affect psoriasis, eg, oral or 
injectable (eg, intraarticular, intramuscular, or intravenous) corticosteroids, 
retinoids, methotrexate, cyclosporine, fumaric acid derivatives, sulfasalazine, 
hydroxycarbamide (h ydrox yurea), azathioprine, intramuscular gold;
c.Psoralen + UVA phototherap y (PUVA ).
Must be discontinued for at least 2weeks prior to first dose of study  drug:
a.Topi[INVESTIGATOR_488022], eg, corticosteroids, tars, 
keratol ytics, anthralin, vitamin D analogs, and retinoids.
b.Exceptions – the following topi[INVESTIGATOR_488023]: non medicated 
emollients for use over the whole bod y; low or least potent (Class 6 or 7) 
topi[INVESTIGATOR_488024], soles, face, and intertriginous areas only ; 
tar and salicy lic acid preparations for the scalp only , and shampoos f ree of 
corticosteroids for the scalp only .  See details inPermitted Concomitant 
Topi[INVESTIGATOR_488025].
c.UVB (narrowband or broadband) phototherap y.
PF-[ADDRESS_627040] udy drug or 5 half-lives (if known), whichever is longer, or until 
lymphocy te count returns to normal, whichever is longer.
4.Any prior treatment with ustekinumab (Stelara®), guselkumab (gene recombinant), 
risankizumab (gene recombinant) or non B cell-specif ic lymphocy te depleting 
agents/therapi[INVESTIGATOR_014] (eg, alemtuzumab [CamPath®], alky lating agents 
[eg,cyclophosphamide or chlorambucil], total lymphoid irradiation, etc); participants 
who have received rituximab or other selective B- lymphocy te depleting agents 
(including experimental agents) within 6months of first dose of stud y drug or 
5half-lives (if known), whichever is longer, or until ly mphocy te count returns to 
normal, whichever is longer .
5. Participants who are likely to receive during the study  any moderate -strong CYP1A2
and CYP3A4 inhibitors/inducers or CYP2D6 inhibitors or MATE substrates as listed 
in Appendix [ADDRESS_627041] the study  site investigator promptl y if 
there are an y intended changes or additions to concomitant medications.
It is recommended that participants avoid changing other prescription or non- prescription 
drugs, vitamins, and dietary  supplements within 7 days or 5 half-lives (whichever is longer) 
prior to the first dose of study  medication and throughout the stud y.
All concomitant medication taken during the stud y must be recorded with indication, daily 
dose, and start and stop dates of administration.
Medications taken after informed consent is obtained (but before the first dose of study  
medication) will be documented as prior medications.  Medications taken after the first dose 
of study  drug has been administered will be documented as concomitant medications.
6.5.1. Rescue Medic ine
There is no rescue therapy to reverse the adverse events ( AEs) observed with PF-06826647 ; 
standard medical supportive care must be provided to manage the AEs. 
6.6. Dose Modification
Treatment assignment inthe Extension Treatment Period will be predetermined according to 
the Scheme shown in Section 1.2.  Participants who are in the p lacebo, 50 mg, or 100 mg 
treatment arms will be assigned to either 200 mg or 400 mg PF -06826647 in the Extension 
Treatme nt Period.  Allocation to either dose in the Extension Treatment Period will be based 
on an initial treatment assignment at randomization.  No dose adjustment is allowed during 
the study . 
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 536.7.Intervention after the End of the Study
No intervention will be provided to study  participants at the end of the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
In rare instances , it may  be necessary  for a participant to permanentl y discontinue the 
investigational product.  Per the study  estimands, if investigational product is permanentl y 
discontinued, the participant will proceed to Early Termination per Schedule of Activities.  
The site will inform s ponsor m edical m onitor or s ponsor clinician if the below criteria for 
permanent discontinuation of the I P are triggered.
Any participant meeting discontinuation criteria must have an Earl y Termination visit with 
their first visit occurring [ADDRESS_627042] dose whenever possible and continue visits 
per Investigator’s discretion until the event has returned to normal or baseline levels or is 
deemed clinicall y stable. 
The only  exception to this is when a participant specificall y withdraws cons ent for an y 
further contact [CONTACT_488054].  
Note that discontinuation of the investigational product does not repre sent withdrawal from 
the study .
Participants experiencing a thrombotic event as part of a serious adverse event must be 
discontinued from further IP administration and referred to a specialist for further evaluation 
of possible hy percoagulable state, as per local guidelines.
ECG Changes
A participant who meets either bulleted criterion below based on the average of triplicate 
ECG readings will be withdrawn from the I P administration. 
QTcF >500 msec ;
Change from baseline: QTc >60 msec .
If a clinically  significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the investigator or qualified designee will determine if 
the participant can continue in the study  and if any change in parti cipant management is 
needed.  This review of the ECG printed at the time of collection must be documented.  Any  
new clinicall y relevant finding should be reported as an AE.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 54Laboratory Abnormalities
All the following laboratory abnormalities require discont inuation if they  areconfirmed.  
Confirmation through re -testing should occur within 48 hours:
Laboratory Variable Laboratory Value
Hem atology
Absolute Neutrophil Count <1000/mm3; <1.0 x109/L
Hem oglobin <10.0 g/dL; <6.2 mmol/L; <100 g/L
Platelet count <75,000/mm3; <75.0x109/L
Lymphocytes <500/mm3; <0.5x109/L
Chemistry
ASTa>3xULN
ALTa>3xULN
Total bilirubinb>1.5x ULN
a.Additional investigations, such as revie w of ethanol, recreational drug and dietary supplement consumption 
should be done; testing for acute hepatitis A, B or C infection and biliary tract imaging should be promptly 
discussed with sponsor medical monitor.
b.Total bilirubin >1.[ADDRESS_627043]; participants with a history of Gilbert's syndro me may have a direct bilirubin 
measured and w ould be eligible for this study pr ovided the direct bilirubin is < ULN .
Pregnancy
If pregnancy  is confirmed by  [CONTACT_488055] ( -hCG ) testing at 
any time, then the sponsor c linician or sponsor m edical monitor should be notified 
immediately .
Suicidality
Participants triggering criteria for suicidal ideation and behavior as described in 
Section [IP_ADDRESS] .
See the SoA for data to be collected at the time of intervention discontinuation and follow -up 
and for an y further evaluations that need to be complet ed.
7.2.Participant Discontinuation/ Withdrawal f rom the Study
A participant may  withdraw from the study  at an y time at his/her own request or may be 
withdrawn at an y time at the discretion of the investigator for safety, behavioral, compliance, 
or administrat ive reasons.
At the time of discontinuing from the stud y, if possible, an earl y termination visit should be 
conducted.  See the SoA for assessments to be collected at the time of stud y discontinuation 
and follow -up and for any further evaluations that need to be completed. 
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 55The Early Termination visit applies only  to participants who are randomized and then are 
prematurel y withdrawn from the study.  Participants should be questioned regarding their 
reason for with drawal .  The participant will be permanently discontinued both from the study  
intervention and from the study  at that time.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples, but data alread y generated from the samples will continue to be available and may 
be used to protect the integrity  of existing anal yses.  The investigator must document any  
such requests in the site study  records.
If the participant withdraws from the study  and also withdraws consent (se e below) for 
disclosure of future information , no further evaluations should be performed, and no 
additional data should be collected.  The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
When a participant withdraws from the study  because of an SAE, the SAE must be recorded 
on the CRF and reported on the Clinical Trial ( CT)SAE Report.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so longas the participant ’s safet y was preserved.
For participants who discontinue early from the Investigational Treatment Period prior to the 
Week 16visit, orthose who discontinue earl y from the Extension Treatment Period prior to 
the Week 40visit, should perform the procedures scheduled at the Earl y Termination (ET) 
visit.
See Section 10forGuidelines for Safet y Monitoring and Discontinuations.
Withdrawal of Consent: 
Participants who request to discontinue receipt of study  treatment will remain in the study
andproceed to ET visit as soon as possible.   Whenever possible, these participants should 
have one visit approximately  two we eks after the last dose (Week 20 or 44 Follow up visit 
assessments) and/or at least [ADDRESS_627044] or also from study  
procedures and/or posttreatment study follow -up, and entered on the appropriate CRF pa ge.  
In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly  available information should be used to determine vital status only as appropriately  
directed in accordance with local law.
PF-[ADDRESS_627045] be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_288949]/or 
should continue in the study ;
Before a participant is deemed lost to follow-up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessar y, a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record ;
The investigator should inquire about the reason for withdrawal, request t hat the 
participant return all unused investigational product(s), request that the participant
return for a final visit, if applicable, and follow up with the participant regarding an y 
unresolved adverse events (AEs);
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study  as a whole ishandled as part of Appendix 1.
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an ap propriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any  study -specific procedures.
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue study  
intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
PF-[ADDRESS_627046], or qualified medical professional and should be performed by  [CONTACT_488056].
Detailed descriptions for the PGA and patient reported outcomes ( PROs) areprovided in 
Appendices 10-17.
8.1.1. Psoriasis Area and Severity Index (PASI)
The Psoriasis Area and Severit y Index quantifies the severit y of a participant’s psoriasis 
based on both lesion severity  and the percentage of body  surface area affected.
Lesion severit y: the basic characteristics of psoriatic lesions – erythema, induratio n and 
scaling –provide a means for assessing the severity  of lesions.  Assessment of these three 
main signs is performed separately for four areas of the body : head, upper limbs, trunk, and 
lower limbs.  Average erythema, induration and scaling are rated for each body  area 
according to a 5 -point scale: 0, no involvement; 1, slight; 2, moderate; 3, marked; 4, very  
marked.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 58Body surface area (BSA) involvement: the extent (%) to which each of the four areas of the 
body  is affected by  [CONTACT_153849] a numerical score according to the following area 
scoring criteria: 0, no involvement; 1, >0 to 9%; 2, 10 to 29%; 3, 30 to 49%; 4, 50 to 69%; 
5, 70 to 89%; 6, 90 to 100%.
Component Scoring Criteria for the Psoriasis Area and Severity Index (PASI)
Component Score Description
Erythema (E)
0 No involvement None; may  have residual hy perpi[INVESTIGATOR_371]
1 Slight Pi[INVESTIGATOR_22764]
2 Moderate Darker pi[INVESTIGATOR_8745]- red
3 Marked Red
4 Very  Marked Extremely  red, “beefy ” red
Induration (I)
[ADDRESS_627047], sharp borders
Scaling (S)
[ADDRESS_627048] lesions partially  covered
3 Marked Coarser thick scale, nearly  all lesions covered, rough
4 Very  Marked Very  thick scale, all lesions covered, very  rough
Percent BSA with Psoriasis : the extent (%) to which each of the four bod y regions is 
involved with psoriasis is categorized using a non-linear scaling method to a numerical area 
score according to the following BSA scoring criteria ( Table 4). 
Table 4. Psoriasis Area and Severity Index (PASI) Area Score Criteria
Percent Body Surface Area 
(BSA) with PsoriasisArea Score
0% (no involvement) 0
>0-9% 1
10-29% 2
30-49% 3
50-69% 4
70-89% 5
90-100% 6
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 59Calculating PASI
Body Region Weighting: each bod y region is weighted according to its approximate 
percentage of the whole body  (Table 5).
Table 5. Psoriasis Area and Severity Index (PASI) Area Score Criteria
Body Region Body Region Weighting
Head and Neck 0.1
Upper Limbs 0.2
Trunk (including axillae and groin) 0.3
Lower Limbs (including buttocks) 0.4
In each bod y region, the sum of the Severity  Scores for ery thema, induration and scaling is 
multiplied by  [CONTACT_488057] b y the Bod y Region Weighting to provide a bod y region 
value, which is then s ummed across all four body  regions resulting in a PASI  score as 
described in the following equation: 
PASI  =0.1Ah(Eh + Ih + Sh) + 0.2Au(Eu + Iu + Su) +
0.3At(Et + It + St) + 0.4Al(El + Il + Sl)
where A = Area Score; E = erythema; I =induration; S = scaling; h = head; u = upper limbs; t = trunk; 
l =lower limbs .
The PASI  score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores 
representing increasing severit y of psoriasis.  The PASI  score will be used for the primary  
analysis.
Calculation of PASI  will be done centrall y by [CONTACT_488058].
Linear Method Psoriasis Area and Severity Index (L PASI)
A second method of calculating PASI will also be performed.  A linear scaling method will 
be applied to the Psoriasis Area and Severi ty Index calculation, adapting the classic 
calculation b y using the actual percentage bod y surface area involved in psoriasis rather than 
categorizing the percentage involvement on a 7 point scale. 
The linear scaling method will be calculated from the stu dy database; investigator sites will 
only perform the classic PASI  calculation during the study .  The L PASI  score will be used 
for a sensitivity anal ysis.
L-PASI Calculation
L-PASI = 0.1(6xBh)x(Eh + I h + Sh) + 0.2(6Bu)x(Eu + Iu + Su) +
0.3(6xBt)x(Et + I t + St) + 0.4(6xBl)x(El + I l + Sl)
where B = percentage area of involvement; E = erythema; I =induration; S = scaling; h =head; u = upper 
limbs; t = trunk; l = lower limbs
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 608.1.2. Physician Global Assessment (PGA)
The Phy sician Global Assessment of psoriasis is s cored on a 5 -point scale, reflecting a global 
consideration of the ery thema, induration and scaling across all psoriatic lesions.  Average 
erythema, induration and scaling are rated separately  over the whole bod y according to a 
5-point severity  scale , scored from 0 to 4, with appropriate morphologic descriptors.  The 
severit y rating scores are summed and the average taken – the total average is rounded to the 
nearest whole number score to determine the PGA (See Appendix 17 ).
The 5 -point scale for PGA is: 0, “clear”; 1, “almost clear”; 2, “mild”; 3, “moderate”; 
4“severe” (Table 7).
Table 6. Component Scoring Criteria for the Physician's Global Assessment (PGA)
Score Description
Erythema (E)
0 No evidence of erythema (post -inflammatory hyperpi[INVESTIGATOR_119065]/or hypopi[INVESTIGATOR_22765])
1 Light pi[INVESTIGATOR_8745]
2 Light red
3 Red
4 Dark, deep red
Induration (I)
[ADDRESS_627049]/sharp borders
Scaling (S)
0 No evidence of scaling
1 Occasional fine scale
2 Fine scale predominates
3 Coarse scale predominates
4 Thick, coarse scale predominates
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 61Table 7. Physician's Global Assessment (PGA) Score
Physician’s Global Assessment Description
[ADDRESS_627050] individual scores for (E + I 
+ S)/[ADDRESS_627051] individual scores for (E + I 
+ S)/[ADDRESS_627052] individual scores for (E + I 
+ S)/[ADDRESS_627053] individual scores for (E + I 
+ S)/3 that rounds to 4
Note: Calculated arithmetic average of individual signs severity scores [(E + I + S)/3] is rounded to the nearest whole number score (eg, if total ≤2.49, score = 2; if total ≥2.50, 
score = 3).  Calculation will be done centrally by [CONTACT_488058].
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 62 
 
8.1.4. Rater Qualifications 
For specific rating assessments, only qualified raters will be allowed to evaluate and/or rate 
participants in this study.  The minimum qualifications a rater must meet for each study rating assessment will be outlined in the Rater Assessment Manual provided to each 
participating site.  The level of experience with the target population (or equivalent), specific 
scale experience (or equivalent), and certification required (if applicable) will be listed and used to determine whether a rater is approved for a given assessment.  Proposed raters who do not meet specific criteria but who may be qualified based on unique circumstances may be individually reviewed by [CONTACT_22820] a waiver may be issued.  The rater must become certified to perform selected study assessments before theycan participate in the conduct of the study.  For specifically defined assessments, rater training and standardization exercises may be conducted, and written and signed documentation will be provided by [CONTACT_22821]’s certification.  In return, each site will be provided written and signed documentation outlining each rater’s certification for specific study assessments.  Recertification may be required at periodic intervals during the study.  The raters who administer specific study assessments will be documented in a centralized location and all site staff who administer ratings will be verified in the site study documentation during the conduct of the study.
8.2. Safety Assessments
Planned time points for all safety assessments are provided in the SoA.  Unscheduled clinical 
laboratory measurements may be obtained at  any time during the study to assess any 
perceived safety concerns.CCI
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 638.2.1. Assessments at Screening only
[IP_ADDRESS]. Tuberculosis (TB) Testing
Participants should be screened for TB using an Interferon gamma release assay  (IGRA) per 
local guidelines.  IGRA will be tested during screening or within 12 weeks prior to 
Screening .  The following are acceptable IGRA assay s:  T SPOT®TB test (preferable, where 
available), QuantiFERON®TB Gold In Tube test (QFT GIT) and QuantiFERON®TB Gold 
test (QFT G).  Site personnel should follow the processing and analy ses steps based on the 
assay  chosen.  Ensure incubation steps are followed as appropriate.   
Documentation of IGRA product used and the test result must be in the participant’s source 
documentation.
If the results of the IGRA are indeterminate, the test may  be repeated once , and if a negative 
result is obtained, enrollment may  proceed.  A positive test on repeat is exclusionary .
Participants with repeat indeterminate IGRA results may be enrolled after consultation with 
pulmonary  or infectious disease specialist that determines low risk of infection (ie, 
participant would be acceptable for immunosuppressant (eg, anti -TNF tumor necrosis factor ) 
treatment without additional action).
Participants who test positive for QFT -G/QFT -GIT test, but in the opi[INVESTIGATOR_488026]. Participant s will be eligible if the repeat 
test is negative before the randomization.
[IP_ADDRESS]. Chest Radiograph
Participants must have chest radiograph taken at Screening and read b y a qualified 
radiologist.  Documentation of the official reading must be located and available in the 
source documentation .
If chest radiograph has been taken within [ADDRESS_627054] x -ray (posterior -anterior an d lateral views are 
recommended, however local guidelines should be followed) or other appropriate diagnostic 
image (ie, computed tomography or magnetic resonance imaging [MRI ]). Participants with 
evidence of currentl y active TB, general infections, heart failure or malignancy will be 
excluded.  Participants with changes suggestive of untreated latent or active TB infection 
may be enrolled after consultation with a pulmonary  or infectious disease spe cialist who 
determines alow risk of infection.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Medical History
Investigators should make all reasonable efforts to obtain a n accurate and complete medical 
history  and history  of prior medication use when evaluating whether a participant is eligible 
for the study .  The following will be collected at Screening: complete medical history , 
psoriasis disease history  (including disease duration and prior treatments) ,and alcohol and 
tobacco use history .
If the status of a participant’s medical history  is in doubt or information pertaining to a 
critical variable is conflicting, every  reasonable step to secure proper documentation of 
correct medical status should be attempted.  Documentation of the medical and medication 
histories over the protocol defined time peri ods should be available for sponsor review 
during the source data verification process.   Questions about prior medications or eligibility  
should be directed to the sponsor c linician or sponsor medical m onitor.
[IP_ADDRESS]. Suicidal Ideation and Behavior Risk Monitoring
The Columbia Suicide Severit y Rating Scale (C -SSRS Appendix 9) is a validated tool to 
evaluate suicidal ideation and behavior .11Atthe screening and baseline visit, if there are 
“yes” answers on items 4, [ADDRESS_627055] 5 years, the par ticipant will be excluded from the study .
8.2.2. Assessment During Study
[IP_ADDRESS]. Full Physical and Brief Physical Examinations
Full phy sical examinations must be performed by  [CONTACT_093], sub -investigator, or a 
qualified healthcare professional per local guidelines.  A full phy sical examination will 
include assessments of the general appearance, skin, head, ey es, ears, nose, throat, 
cardiovascular, respi[INVESTIGATOR_696] (lung) , gastrointestinal, and neur ological s ystems.  I nvestigators 
should pay  special attention to clinical signs related to previous serious illnesses.
A brief examination will include assessments of the skin (both psoriasis and non -psoriasis 
skin) and body  systems with any  symptoms reported by  [CONTACT_488059]. 
Any clinically  significant changes from the most recent ph ysical examination should be 
recorded as adverse events (AEs).   Investigators should pay  special attention to clinical signs 
related to previous serious illnesses.
Full and brief ph ysical exams will be performed as specified in Schedule of Activities .
[IP_ADDRESS]. Weight and Height
It is recommended that weight be measured in kilograms (kg) and that height be measured in 
centimeters (cm).   Height and weight will be measured to one decimal place.
For measuring weight, a scale with appropriate range and resolution should be used and must 
be placed on a stable, flat surface.  Participants should remove shoes, bulky  layers of 
clothing, and jacke ts so that only  light clothing remains. 
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Vital Signs (Blood pressur e, pulse rate, and temperature)
Single sitting blood pressure (BP) , pulse rate, and temperature will be measured at times 
specified in the Schedule of Activities.  Additional collection times or changes to collection 
times will be permitted, as necessary  to ensure appropriate collection of safety  data.
Vital signs should be performed before laboratory blood collection after at least [ADDRESS_627056]. 
Sitting blood pressure (preferred but not required) will be measured with the participant ’s 
arm supported at the level of the heart and recorded to the nearest mm Hg.  It is preferred that 
the same a rmbe used throughout the study .
The same size BP cuff, wh ich has been properl y sized and calibrated, will be used to measure 
BP each time.  The use of automated devices for measuring BP and pulse rate is acceptable, 
although, when done manually, pulse rate will be measured in the brachial/radial artery  for at 
least 30 seconds.  When the timing of these measurements coincides with a blood collection, 
it is preferred that vital signs be obtained prior to the nominal time of blood collection.
Body temperature may be collected using t ympanic, oral (preferred) , or axi llary methods and 
that the same method be used con sistently  throughout the study .
8.2.3. Electrocardiograms
Six singlicate standard 12-Lead E CGs should be collected at times specified in the SoA
section of this protocol using an ECG machine that automatically  calculates the heart rate and 
measures pulse rate ( PR), QT, and QTc intervals and QRS complex .  All scheduled ECGs 
should be performed after the participant has rested quietly  for at least 10 minutes.  
Consistent met hods across visits is recommended.
ECGs should be performed bef ore laboratory  blood collection, BP, and pulse rate.
To ensure safet y of the participants, a qualified individual (eg, sub -investigator) at the 
investigator site will make comparisons to baseline measurements taken at baseline .  A cop y 
of the ECG should be available as source documents for review.  ECGs will be read lo cally  
during the dosing period.
If a postdose QTc interval remains ≥30msec from the baseline andis >450 msec; or b) an 
absolute QTc value is ≥500 msec for an y scheduled ECG for greater than 4 hours (or sooner ,
at the discretion of the investigator), or QTc intervals get progressivel y longer, the participant
should undergo continuous ECG monitoring.  A cardiologist should be consulted if QTc 
intervals do not return to less than the criterion listed above after 8 hours of monitoring (or 
sooner ,at the discretion of the investigator). 
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 66In some cases, it may  be appropriate to repeat abno rmal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality .  It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read QTc 
value is prolonged, as defined ab ove, repeat measurements may  not be necessary  if a 
qualified medical provider ’s interpretation determines that the QTc values are in the 
acceptable range.
ECG values of potential clinical concern are listed inAppendix 7.
8.2.4. Clinic al Safety Laboratory Assessments
See Appendix [ADDRESS_627057] any  
clinically  relevant changes occurring during the study  in the AE section of the CRF.  
Clinically  significant abnormal laboratory  findings are those which are not assoc iated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 28days after the last dose of study  intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline wi thin a period judged reasonable by  [CONTACT_1275], the etiology  should be identified, and the sponsor notified.
All protocol -required laboratory  assessments, as defined in Appendix [ADDRESS_627058] be conducted 
in accordance with the l aboratory  manual and the SoA.
If laboratory  values from non- protocol -specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in participant management or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
8.2.5. Suicidal Ideation and Behavior Risk Monitoring 
Participants meeting exclusionary  criteria ( Section 5.2) for suicidal ideation/behavior will be 
excluded from study  participation.   It is recommended the participant’s primary  care 
physician (PCP) is informed if this exclusion criterion is met, and the participant referred to a 
mental health professional, either b y the PCP or the investigator according to their usual 
practice.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Columbia Suicide Severity Rating Scale 
The Columbia Suicide Severit y Rating Scale (C -SSRS)11is a validated tool to evaluate 
suicidal ideation and behavior ( Appendix 9 ).  “Lifetime” version will be used at screening 
and baseline and the “since last visit” version will be used in all subsequent visits.
If at an y visit, there are “YES” answers on items 4, 5 or on an y behavioral question of the 
C-SSRS, a risk assessment should be done immediately  by a qualified medical health 
practitioner for appropriate evaluation and treatment.   If the participant cannot be seen b y a 
mental health professional within 24 hours, then the participant should be sent to a local 
emergency  room for ps ychiatric assessment.  If these answers occurred after IP dosing
(ie,post-Day 1), IP will be temporaril y discontinued until further evaluation.   This evaluation 
will help determine whether it is safe for the participant to continue to participate in the trial.  
Participants who answer “ YES” on items 4, 5 or on any  behavioral question of the C -SSRS 
on more than one occasion during a trial will be discontinued from the trial.
8.2.6. Herpetiform Rash Surveillance 
For an y occurrence of a suspected herpetiform rash (eg, herpes zoster and herpes sim plex), 
specimens for viral deoxy ribonucleic acid (DNA) anal ysis will be obtained: A swab of the 
affected area will be collected for confirmation; a blood sample for viral surveillance will be 
collected for the anal ysis of viral load.  Details for these collections will be provided in the 
laboratory  manual .
8.2.7. G lomerular Filtration R ate
Serum creatinine is the best known standard test for monitoring renal function.   Serum 
creatinine will be measured as part of serum chemistry at times specified in the Schedule of 
Activities sectionof the protocol .  Serum creatinine elevations above the ULN will be 
followed until resolution or baseline.  Serum creatinine based eGFR will be calculated.  
eGFR will be calculated at corresponding times per Schedule of Activities. 
The eGFR will be calculated using the equation developed by  [CONTACT_488060][INVESTIGATOR_8849] (CKD -EPI).[ADDRESS_627059] 25 mIU/mL.  Pregnancy  tests will be performed in women of child -bearing 
potential ( WOCBP) at the times listed in the SoA .  Following a negative pregnancy  test result 
at screening, appropriate contraception must be commenced, and a second negative 
pregnancy  test result will be required at the baseline visit prior the participant’s receiving the 
investigational product.   Pregnancy  tests will also be done whenever 1 menstrual cy cle is 
missed during the active treatment period (or when potential pregnancy  is otherwise 
suspected) and a t the end of the study .  Pregnancy  tests may  also be repeated if requested b y 
institutional review boards (I RBs)/ethics committees (ECs) or if required by  [CONTACT_13125].  If a urine test cannot be confirmed as negative (eg, an ambiguous result), a 
serum pregnancy  test is required.  In such cases, the participant must be excluded if the 
serum pregnancy  result is positive .
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 688.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether it 
meets the criteria for classification as an SAE or that caused the participant to discontinue the 
PF-06826647 (see Section 7). 
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Inform ation
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study (ie, before undergoing 
any study -related procedure and/or receiving investigational product), through and including 
a minimum of [ADDRESS_627060].
For participant s who are screen failures, the active collection period ends when screen failure 
status is determined.
Medical occurrences that begin before the start of study  intervention but after obtaining 
informed consent will be recorded on the Medical History /Current Me dical Conditions 
section of the case report form (CRF), not the AE section.
Follow -up by  [CONTACT_74095] a level acceptable to the investigator, and 
[COMPANY_007] concurs with that assessment.
Investigators are not obligated to activel y seek AE sor SAE safter conclusion of the study  
participation .  However, if the investigator learns of an y SAE, including a death, at an y time 
after a partici pant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the study  intervention or study  participation, the investigator must 
promptly  notify  the sponsor.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period are reported to [COMPANY_007] 
Safety on the CT SAE Report Form i mmediatel y and under no circumstance should this 
exceed 24 hours, as indicated in Appendix 3 . The investigator will submit any updated SAE 
data to the sponsor within 24 hours of it being available .
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 69SAEs occurring in a participant after the active collection period has ended are reported to 
[COMPANY_007] Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to [COMPANY_007] Safety .
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing c ausality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs.   Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix 3 .
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the sa fety of a stud y intervention under clinical investigation.   The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, institutional review boards (IRB s)/ethics committees 
(ECs), and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R s) according to local regulatory requirements and sponsor policy  and 
forwarded to investigators as necessary .
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 70An investigator who receives an investigator safety report describing a nSAE or other 
specific safet y information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it along with the investigator’s brochure and will notify  the IRB/EC, if 
appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
[IP_ADDRESS]. Exposure During Pregnancy
Details of all pregnancies in female participants and, if indicated, femal e partners of male 
participants will be collected after the start of study  intervention and until at least [ADDRESS_627061] dose.
If a pregnancy  is reported, the investigator should inform the sponsor within [24 hours] of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 4 .
Abnor mal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered SAEs.
[IP_ADDRESS]. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to [COMPANY_007] Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form .  An exposure during breastfeeding report is not created when a [COMPANY_007] 
drug specifically  approved for use in breastfeeding women (eg, vita mins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact [CONTACT_8898], which may  or may  not lead to the occurrence of an AE.
An occupational exposure is repor ted to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a participant enrolled in the study , the 
information is not rec orded on a CRF; however, a copy of the completed CT SAE Report 
Form is maintained in the investigator site file .
8.3.6. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong participant, or at the wrong time, or at the wrong dosage strength .
PF-[ADDRESS_627062] SAE Report 
Form to [COMPANY_007] Safety Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only if associated with an SAE
Medication errors include:
•Medication errors involving participant exposure to the investigational product;
•Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately.Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on an AE page of the CRF. 
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_627063]
within a 24-hour time period will be considered an overdose.
Sponsor does not recommend specific treatment for an overdose.In the event of an overdose, the investigator should:
1. Contact [CONTACT_10990].2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities until 
PF-06826647 can no longer be detected systemically (at least 3 days).
 
 
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 724. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.
5. Overdose is reportable to Safety only when associated with an SAE .
Decisions regarding dose interruptions or modifications will be made by [CONTACT_78256].
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 CCI
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 73 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 75 
 
Unless prohibited by [CONTACT_168086]/EC decision, participants will be asked to 
indicate on the consent document whether they will allow their banked samples to also be used to design and conduct research in order to gain a further understanding of other diseases and to advance science, including development of other medicines for patients.  This component of the sampling banking is optional for participants; they may still participate in the study even if they do not agree to the additional research on their banked samples.  The optional additional research does not require the collection of any further samples.
SeeAppendix [ADDRESS_627064]-effectiveness/utility modeling.  The EQ5D-5L is summarized below in the patient reported outcomes measures section. 
8.10. Patient Reported Outcome Measures
Every effort should be made for the participant to complete all patient reported outcome 
(PRO) questionnaires before any other assessments except at Baseline when eligibility needs to be confirmed.  All PROs should be completed in the following order: Psoriasis Symptom Inventory (PSI), Peak-Pruritus Numerical Rating Scale (PP-NRS),  
 will be completed as a diary from baseline to Day 15.  Post Day 15, these scales 
will be completed at the site.  At site visits participants will complete PROs in the following order: Psoriasis Symptom Inventory (PSI), PP-NRS,  
 
 The amount 
of time required for a participant to complete the PRO questionnaires is approximately 10-25 minutes (depending on the visit and associated PROs). 
Once participants meet all eligibility criteria, they will be provided a handheld device 
(provided by [CONTACT_456]) for the PSI (both 24-hour recall and 7-day recall), PP-NRS, a  
to be completed at home prior to first dose of the day.  .  All PROs are 
to be completed as per the time points defined in the Schedule of Activities . 
Delegated site staff will oversee the use of electronic Patient Reported Outcomes (ePRO) 
devices.  Completion of PROs will be monitored for adherence.  Delegated site staff will review adherence to all applicable PROs with participants at each visit and counsel as appropriate.  If a participant has repeated non-adherence, the participant should be retrained on use of the device.  If a participant is unable to complete ePROs due to documented technical issue or disability or other limitation (eg, difficulty with manual dexterity or vision), the participant will be permitted to enter or remain in the study and a valid alternate CCI
CCI
CCI
C
CI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 76source of data entry is completed and reviewed by [CONTACT_22830].  This may 
include for example reading the questions verbatim to the participant and entering participant selection of responses by [CONTACT_7893].
8.10.1. Psoriasis Symptom Inventory
The Psoriasis Symptom Inventory (PSI) is a self-administered [ADDRESS_627065] 7 days(Appendix 10 ).
[ADDRESS_627066] 2 weeks up to Week 2 visit (inclusive), the PSI will be 
administered daily using a recall period of [ADDRESS_627067] 7 days.  The 
measure includes concepts of itch, pain, burning, stinging, cracking, scaling, flaking, and redness.  Participants are asked to respond to each item using a 5-point Likert response scale: 0: not all severe, 1: mild, 2: moderate, 3: severe and 4: very severe.  PSI should be completedas described in the Schedule of Activities .
8.10.2. Peak-Pruritus Numerical Rating Scale
The intensity of pruritus will be assessed by a Peak-Pruritus Numerical Rating Scale 
(PP-NRS), an 11-category numeric rating scale from 0 to 10, which is patient reported (Appendix 11 )
14,[ADDRESS_627068] 24 hours, 
anchored by [CONTACT_80209] “no itch” (0) and “worst itch imaginable” (10) at the ends. 
 
 
 
  
 
 
 
   
 
 
 
 
 CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 77 
 
 
 
 
 
 
 
 
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a statistical analysis plan (SAP), which will be maintained by [CONTACT_456].  The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Estimands and Statistical Hypotheses
9.1.1. Estimands
The primary estimand will be the population average treatment effect on PASI [ADDRESS_627069] will be the differences in the proportions of successes in each treatment arm compared to the 
corresponding placebo.
All other secondary continuous clinical endpoints will be analyzed using estimand E2, while 
all other key secondary categorical clinical endpoints will be analyzed using the primary estimand E1 as described above.   
Other estimands may be used for some of the primary and 
secondary endpoints as a means to examine the robustness of the results and to compare to CCI
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 78available literature as needed.  Details of these analyses will be presented in the statistical 
analysis plan (SAP).
9.2. Sample Size Determination
The primary endpoint in this study is the PASI 90 response rate at Week 16.  Assuming a 
PASI 90 response rate as 5% for the placebo group, and placebo corrected effect 35% or greater for one of the treatment groups, a total of N=[ADDRESS_627070] 90% power for the lower doses due to Bonferroni multiplicity adjustment with 1-sided type-I error rate of 5% and 2:1:1:2:2 allocation ratio of placebo, 50 mg, 100 mg, 200 mg, and 400 mg.  The total sample size includes a sample size of 32 completers per arm for placebo, 200 mg and 400 mg, and 16 completers per arm for 50 mg and 100 mg.  Accounting for a 20% chance of drop out, approximately a total of 160 participants will be enrolled in this study.
9.3. Populations for Analysis
For purposes of analysis, the following populations are defined:
Population Description
Safety Analysis Set All participants randomly assigned to IP and who take at least 
[ADDRESS_627071] they actually received.
Defined Population for AnalysisDescription
Modified Intention to 
Treat (mITT)All participants randomly assigned to IP and who take at least 
1 dose of IP.  
 
9.4. Statistical Analyses
The SAP will be developed and finalized before database lock and will describe the 
participant populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data.  This section is a summary of the planned statistical analyses of the primary and secondary endpoints.CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 799.4.1. Efficacy Analyses
Endpoint Statistical Analysis Methods
Primary and 
key secondary: PASI 90 and PASI 75 at Week 16A landmark analysis of the composite endpoint; achieving a PASI 90 
response (a score of 90% improvement from Baseline) without prohibited 
medication, while remaining on study and providing data.  The analysis will 
use the mITT analysis set.  Based on the definition of the composite endpoint all participants in the mITT set will have a response for all visits 
(ie, there is no missing data).  The proportions responding and the risk 
difference between treated arms and their corresponding placebo arm will be analyzed using an unconditional exact method: risk differences and 
corresponding 2-sided unconditional exact 90% confidence intervals will be 
computed using the Chan and Zhang (1999) method.  Multiplicity adjustment will be utilized; details of multiplicity adjustment will be 
provided in the SAP.
Other continuous secondary endpoints at time points specified in the Schedule of Activities
including; absolute PASI, change from baseline PASI, percent change from baseline PASI, absolute and change from baseline Itch Severity Score, absolute and change from baseline Psoriasis Symptom Inventory will be analyzed as described for the E2 estimand along with descriptive statistics and possibly graphical displays.  No adjustments for multiplicity will be made for these endpoints.
Other binary secondary endpoints at time points specified in the Schedule of Activities
including, PASI 50, PASI 100, PGA of clear or almost clear and proportions of participants achieving a Psoriasis Symptom Inventory Score of 0 or 1 will be analyzed as described for the primary estimand along with descriptive statistics and possibly graphical displays. No adjustments for multiplicity will be made for these endpoints.
 
All endpoints in Extension Treatment Period will be analyzed with descriptive statistics and 
graphical displays when appropriate.  Details of the analyses of the Investigational Treatment Period and Extension Treatment Period will be included in the Statistical Analysis Plan (SAP).
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 809.4.2. Safety Analyses
All safety analyses will be performed on the safety population.
Endpoint Statistical Analysis Methods
Primary The safety data will be summarized in accordance with [COMPANY_007] Data 
Standards.  All participants who receive IP (safety population) will be 
included in the safety analyses.  All safety data will be summarized descriptively through appropriate data tabulations, descriptive statistics, 
categorical summaries, and graphical presentations.  Safety endpoints for the 
study include:
•Treatment-emergent AEs and SAEs.
•Withdrawals from active treatment due to AEs.
•Serious infections, defined as any infection (viral, bacterial, and 
fungal) requiring hospi[INVESTIGATOR_22769].
•Safety laboratory tests (eg, hematology [including coagulation 
panel], chemistry and lipid profiles).
•Vital signs.
Change from baseline on laboratory data and vital signs will be additionally 
summarized.  Participant listings will also be produced for these safety 
endpoints.
 
[IP_ADDRESS]. Electrocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR 
interval, and QRS complex will be summarized by [CONTACT_22841].
The number (%) of participants with maximum postdose QTc values and maximum increases 
from baseline in the following categories will be tabulated by [CONTACT_3148]: 
Safety QTc Assessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (msec)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >60
In addition, participants with QTcF values >[ADDRESS_627072] 60% of the 
planned participants, ie, approximately 80 participants, complete their study participation through Week 12.  Interim analysis results will be used for internal business decisions regarding future study planning or stoppi[INVESTIGATOR_16589].  Before the interim analysis is instigated, the details of the objectives, decision criteria, dissemination plan and method of maintaining the study blind as per [COMPANY_007]’s SOPs will be documented and approved in theinternal review committee (IRC) charter.  In addition, the analysis details will be documented and approved in an interim analysis SAP or final SAP.
9.5.1. Data Monitoring Committee 
This study will not use a data monitoring committee (DMC).  This study will use an internal 
review committee (IRC) which will be comprised of internal [COMPANY_007] experts, independent of the study team.
Members of the study team will not be part of the IRC.  An unblinded sponsor statistician or 
a clinician who is not directly involved with the study will perform the interim analyses and provide the results only to the IRC.  No randomization information for individual participantswill be reported to the IRC as part of the interim analysis; however, unblinded aggregate results will be reported.
The IRC will be responsible for evaluating safety of participants in the study according to the 
IRC Charter.  The recommendations made by [CONTACT_488061].  [COMPANY_007] will forward such decisions, which may include summaries of aggregate analyses of endpoint events and of safety data that are not endpoints, to regulatory authorities, as appropriate.CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 829.5.2. Safety Adjudication Committees
The identification of events requiring submission to an adjudication/review committee may 
be made by [CONTACT_488062].  Events requiring review, including cardiovascular and venous thromboembolic events may also be identified by [CONTACT_488063]’s study records.  The [COMPANY_007] study team or designee will notify the study site of any events if identified. 
The [COMPANY_007] Study Team or designee will provide a listing of specific documents needed to 
support event adjudication by [CONTACT_488064]/Review Committees. Obtaining and submitting the documentation will be the responsibility of the study site. Event documentation will vary with the event requiring adjudication and may include (but not be limited to): hospi[INVESTIGATOR_8838], operative reports, clinic notes, diagnostic tests, pathology reports, autopsy reports and death certificate information, as applicable.
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 8310. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordanc e with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines ;
Applicable International Council for Harmonisation (I CH) Good Clinical Practice 
(GCP) guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, investigator’s brochure ( IB), and other relevant 
documents (eg, advertisements) must be reviewed and approved by  [CONTACT_177269] I RB/EC by  [CONTACT_20003] b y the IRB/EC 
before the study  is initiated.
Any amendments to the protocol will requi re IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 Code of Federal Regulations ( CFR ), ICH guidelines, the I RB/EC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aw are of any  new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, Sponsor should be informed immediatel y. 
PF-[ADDRESS_627073], and 
of an y serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for pr oviding information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions regarding the 
study .
Participants must be informed that their participation is voluntary .Participants or their 
legally  authorized representative will be required to sign a statement of informed consent that 
meets the requirements of [ADDRESS_627074] (HIPAA) requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. Thelevel of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_160439], by  
[CONTACT_6667]/EC members, and by  [CONTACT_90742].
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D.
Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 85A copy of the ICD(s) must be provided to the participant or the participant’s legally 
authorized representative.
A participant who is rescreened is required to sign another ICD.
 
 
 
 
 
10.1.4. Data Protection
All parties will comply with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study site in encrypted electronic and/or paper
form and will be password protected or secured in a locked room to ensure that only authorized study staff have access.  The study site will implement appropriate technical and organizational measures to ensure that the personal data can be recovered in the event of disaster.  In the event of a potential personal data breach, the study site shall be responsible for determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371].
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, participants will be assigned a single, participant-specific numerical code.Any participant records or data sets that are transferred to the sponsor will contain the numerical code; participant names will not be transferred. All other identifiable data transferred to the sponsor will be identified by [CONTACT_20007], participant-specific code. The study site will maintain a confidential list of participants who participated in the study, linking each participant’s numerical code to his or her actual identity. In case of data transfer, the sponsor will protect the confidentiality of participants’ personal data consistent with the clinical study agreement and applicable privacy laws.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with applicable local laws/regulations.  In addition, [COMPANY_007] reports study results outside of the requirements of local laws/regulations pursuant to its standard operating procedures (SOPs).
In all cases, study results are reported by [CONTACT_4715], accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study or the country in which the study was conducted.CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 86www.clinicaltri als.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007] -sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
product, regardless of the geographical location in which the s tudy is conducted.  US Basic 
Results are generall y submitted for posting within 1 year of the primary  completion date 
(PCD) for studies in adult populations or within [ADDRESS_627075]
[COMPANY_007] posts European Union (EU) Basic Results on EudraCT for all [COMPANY_007] -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the E uropean Medicines Agency  (EMA) website.  Clinical data, under Phase 1 of this 
policy , includes clinical overviews, clinical summaries, CSRs, and appendices containing the 
protocol and protocol amendments, sample CRFs, and statistical methods.  Clinical dat a, 
under Phase 2 of this policy , includes the publishing of individual participant data.  
Policy 0070 applies to new marketing authorization applications submitted via the 
centralized procedure since 01 January 2015 and applications for line extensions and for new 
indications submitted via the centralized procedure since 01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations.  CSRs will have personall y identifiable information 
redacted.
PF-[ADDRESS_627076], including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
The investigator must maintain accurate doc umentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are secur ely stored at the study site in encrypted 
electronic and/or paper form and are password protec ted or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.   This 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk-based initiatives in operations and quality  
such as risk management and mitigation strategies and analytical r isk-based monitoring), 
methods, responsibilities ,and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) ,are provided in the
monitoring plan.
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of par ticipants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed IC Ds, perta ining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 88When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify thesponsor or its agents immediately  ofany regulatory 
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigator will promptly  
provide copi[INVESTIGATOR_488027].  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Documents
Asused in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this study .
A CRF is required and should be completed for each included particip ant.  The completed 
original CRFs are the sole propert y of [COMPANY_007] and should not be made available in any form to 
third parties, except for authorized representatives of [COMPANY_007] or appropriate regulatory  
authorities, without written permission from [COMPANY_007].
The investigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y, and laboratory data entered on the CRFs and any other data collection forms (source 
documents) and ensuring that they are accurate, authentic/original, a ttributable, complete, 
consistent, legible, timely  (contemporaneous), enduring, and available when required.  The 
CRFs must be signed b y the investigator or b y an authorized staff member to attest that the 
data contained on the CRFs are true.  An y correcti ons to entries made in the CRFs or source 
documents must be dated, initialed, and explained (if necessary) and should not obscure the 
original entry . 
In most cases, the source documents are the hospi[INVESTIGATOR_110422].  In 
these cases, data collected on the CRFs must match the data in those charts. 
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigator site and at [COMPANY_007] that clearl y identifies those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document.
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source document s are filed at the investigato rsite.
Data reported on the CRF or entered in the electronic CRF ( eCRF )that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must be 
explained . The investigator may  need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.
PF-[ADDRESS_627077] 
research organization ( CRO )if requested to do so by  [CONTACT_22846]/EC or if such 
termination is r equired to protect the health of study  participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development .
Study  termination is also provided for in the clinical study  agreement.  If there is an y conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
[COMPANY_007] supports the exercise of academic freedom and has no objection to publication by  [CONTACT_28824] (PI) of the results of the study  based on information collected or 
generated b y the PI, whether or not the results are favorable to the [COMPANY_007] product.  However, 
to ensure against inadvertent disclosure of confidential information or unprotected 
inventions, the invest igator will provide [COMPANY_007] an opportunity  to review any  proposed 
publication or other t ype of disclosure of the results of the study (collectively, “publication”) 
before it is submitted or otherwise disclosed.
The investigator will provide any  publication to [COMPANY_007] at least [ADDRESS_627078] publication is 
to be a joint publication covering all investigator sites, and that an y subsequent publications 
by [CONTACT_978] [INVESTIGATOR_488028].  However, if a joint manuscript has not 
been submitted for publication within 12 months of completion or termination of the study  at 
all participating sites, the investigator is free to publish separatel y, participant to the other 
requirements of this section.
For all publications relating to the stud y, the institution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II “Ethical 
Considerations in the Conduct and Reporting of Research” of the Unifor m Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  [CONTACT_4717].
Publication of study  results is also provided for in the clinical study  agreement ( CSA )
between [COMPANY_007] and the institution.  I n this section entitled Publications by  [CONTACT_4718], the 
defined terms shall have the meanings given to them in the CSA.
If there is an y conflict between the CSA and an y attachments to it, the terms of th e CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of study  participants, and the CSA will control as to all 
other issues.
10.1.10. Sponsor’s Qualified Medical Personnel
The con tact information for the sponsor's appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_78276] (SToD) 
system. 
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, participant s are provided with a contact [CONTACT_1137].  The contact [CONTACT_95504], at a minimum, protocol and investigational product identifiers, participant numbers, 
contact [CONTACT_22850], and cont act details for a contact [CONTACT_74072] a medical 
question or problem originating from another healthcare professional not involved in the 
participant ’s participation in the stud y.  The contact [CONTACT_488065]; however, it should be used 
only in the event that the established communication pathway s between the investigator site 
and the study  team are not available.  It is therefore intended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team for 
advice on medical questions or problems that may arise during the stud y.  The contact
[CONTACT_8865] b y the participant directly , and if a participant calls that 
number, he or she will be directed back to the investigator site.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 9110.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol.  Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by [CONTACT_20019]; or as derived from calculated values.  These additional tests would not require additional collection of blood.  Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety concerns.
HematologyaChemistryaUrinalysisaOther
Hemoglobin
Hematocrit
RBC count
MCVMCHMCHC
Reticulocyte count
Platelet countWBC count with differentialTotal neutrophils (%, Abs)Eosinophils (%, Abs)
Monocytes (%, Abs)
Basophils (%, Abs)Lymphocytes (%, Abs)Coagulation Panel
Activated Partial 
Thromboplastin Time (aPTT)Prothrombin 
Time/International 
Normalized Ratio (PT/INR)BUN/urea and creatinine
Glucose
Calcium
SodiumPotassiumChloride
Total CO2 (bicarbonate)
AST, ALTGGTTotal, indirect and direct bilirubin
Alkaline phosphatase
Uric acidAlbuminTotal protein
Creatine kinase (CK) 
Lipid Profile Panel
b
Total CholesterolTriglycerides
HDL-C
LDL-CpH
Glucose (qual)
Protein (qual)
Blood (qual)KetonesNitrites
Leukocyte esterase
UrobilinogenUrine bilirubinMicroscopy
cAt screening only:
•FSHd
•HIV
•TB teste
•HBsAg, HBcAb, HepB reflex 
(HBsAb), if applicable HCVAb 
and/or HBVf.
At visits per SoA:
•Pregnancy test ( β-hCG)g
•Skin swabs for herpetiform 
rashh
•
 
Abbreviations: Abs = absolute; ALT = alanine aminotransferase; aPTT = activated partial thromboplastin time; 
AST = aspartate aminotransferase; β-hCG = beta-human chorionic gonadotropin; BUN = blood urea nitrogen; 
CO2 = carbon dioxide; FSH = follicle-stimulating hormone; GGT = Gamma Glutamyl Transferase; HBV= hepatitis B 
virus; HCV= hepatitis C virus; HDL = high density lipoprotein cholesterol; HIV = Human Immunodeficiency Virus; 
 IGRA = Interferon Gamma Release Assay; INR = international normalized 
ratio; LDL =low density lipoprotein cholesterol; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular 
hemoglobin concentration; MCV = mean corpuscular volume;  PCR = polymerase chain reaction; [COMPANY_003] 
= purified protein derivative; qual = qualitative; PT = prothrombin time; QFT-G = quantiferon-TB-Gold; RBC = red blood cell;  WBC = white blood cell.
a. Safety labs include hematology, chemistry and urinalysis.  Fasting not required unless lipid panel taken.
b. Lipid panel requires fasting (water only) at least 8 hours prior to collection.
c. Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.d. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a 
postmenopausal state in women.
e. TB test must be Interferon Gamma Release Assay (IGRA).
f. HepB reflex testing only if HBsAg negative but HBcAb positive at Screening. If result of HCVAb is positive, or if 
Hepatitis C Virus antibody result is indeterminate, then an HCV RNA AMPLIPREP TAQMAN 2.0 will automatically be performed. HBV DNA monitoring may be applicable in Japan.
g. Serum/urine pregnancy test for WOCBP.
h. In cases of suspected herpetiform rash (eg, suspected herpes zoster and herpes simplex).
Investigators must document their review of each laboratory safety report.CCI
CCI
CCI
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 9210.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study  intervention, whether or not considered 
related to the stud y intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be r eported regardless of 
sequelae.
Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 93participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
Results in death
Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the even t. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually  involving 
at least an overnight stay) at the hospi[INVESTIGATOR_294504]/or 
treatment that would not have been appropriate in the phy sician’s office or outpatient 
setting.  Complications that occur during hospi[INVESTIGATOR_1084].   If a complication 
prolongs hospi[INVESTIGATOR_23919], the event is serious. When in 
doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be 
considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline is not considered an AE.
Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This de finition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 94and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life fun ctions but do not constitute a substantial disruption.
Is a congenital anomaly/birth defect
Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medica l events that may  
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_268678]. These event s should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
10.3.3. Recording/Reporting and Follow -up of AE sand/or SAE s
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording adverse events on the CRF and 
for reporting serious adverse events on the Clinical Trial (CT) Serious Adverse Event (SAE) 
Report Form to [COMPANY_007] Safety.  These requirements are delineated for 3 types of events: (1) 
SAEs; (2) nonserious adverse events (AEs); and (3) exposure to the investigational product 
under study  durin g pregnancy  or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report For m to [COMPANY_007] 
Safety Within [ADDRESS_627079] 
under study  during 
pregnancy  or 
breastfeeding, and 
occupational exposureNone All (and exposure during 
pregnancy  [EDP ]
supplemental form for 
EDP)  
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety . In this case, all participant identifiers, with the exception 
of the participant number, will be redacted on the copi[INVESTIGATOR_488029] s ubmission to [COMPANY_007] Safet y.
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study  and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed as 
severe should not be confused with a nSAE.  Severe is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in t he definition of an SAE, NOT when it is rated as severe.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 96Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship convey s that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the i nvestigator’s brochure (IB) and/or p roduct 
information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality for 
every event b efore the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the investigational product caused 
the event, then the event will be handled as “related to investigational product” for 
reporting p urposes, as defined by  [CONTACT_456] .  In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator must 
record this causal relationship in the source documents and CRF, and report such an 
assessment in the de dicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 97Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE or SAE as fully as 
possible. This may include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare professionals.
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigato r will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours of 
receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is com pleted at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
PF-[ADDRESS_627080] SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to transmit 
this information to [COMPANY_007] Safety .
In circumstances when the fac simile is not working , notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_13187].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 9910.4. Appendix 4: Contraceptive Guidance and Col lection of Pregnancy Information
10.4.1. Male Participant Reproductive Inclusion Criteria
No contraception methods are required for male participants in this study , as the calculated 
safet y margin is ≥[ADDRESS_627081] 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3 ).
OR
Is a WOCBP and using a contraceptive method that is acceptable and highly effective 
(with a failure rate of <1% per year), with high user dependency , as described below 
during the intervention period and for at least [ADDRESS_627082] dose of study  
intervention, which corre sponds to the time needed to eliminate any  study  
intervention(s) .  In addition, a second effective method of contraception, as described 
below, must be used (except for sexual abstinence) .  
The investigator should evaluate the effectiveness of the contrac eptive method in 
relationship to the first dose of study  intervention.
The investigator is responsible for review of medical history , menstrual history , and 
recent sexual activity  to decrease the risk for inclusion of a woman with an earl y 
undetected pregnancy . 
10.4.3. Woman of Childbearing Potential (WOCBP)
A woman is considered fe rtile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study intervention, ad ditional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 100For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview.  The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2. Postmenopausal female:
A postmenopausal state is defined as age 60 yearsor older or no menses for 
12months without an alternative medical cause. 
A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state i n women not using hormonal 
contraception or hormon ereplacement therap y (HRT). 
Females on HRT and whose menopausal status is in doubt will be required to use 
one of the nonestrogen hormonal highl y effective contraception methods if they 
wish to continue t heir HRT during the stud y.  Otherwise, they  must discontinue 
HRT to allow confirmation of postmenopausal status before study  enrollment.
10.4.4. Contracepti onMethods
Highly Effective Methods with Low User Dependency are preferred.  ( Failure rate of <1% 
per year w hen used consistently  and correctly ). 
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation*.
2.Intrauterine device (IUD) .
3.Intrauterine hormone -releasing s ystem (IU S)*.
4.Bilateral tubal occlusion .
5.Vasectomized partner :
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed. If not, an additional highly  effective 
method of contr aception should be used. The s permatogenesis cy cle is 
approximately  90days.
* This requirement may be removed if supported by [CONTACT_488066] (Study C2501005); investigators will be notified and notification s as per local regulatory requirements 
will be completed, as applicable.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 101Highly Effective Methods that are User Dependent 
One of the acceptable barrier methods (described below) must be used in addition to the 
highl y effective methods that are user depend ent except for sexual abstinence.
1.Combined (estrogen -and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation :
Oral;
Intravaginal ;
Transdermal ;
Injectable .
2.Progestogen -only hormone contraception associated with inhibition of ovulation.
3.Sexual abstinence:
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.  The reliability  of sexual abst inence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
Acceptable Contraceptive Barrier Methodsa
1. Male or female condom with or without spermicideb
2.Cervical cap, diaphragm, or sponge with spermicide
3. A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double barrier methods)
a.Considered effective, but not highly effective methods -failure rate of ≥1% per year. Note that periodic 
abstinence (calen dar, symptothermal, post -ovulation methods), w ithdraw al (coitus interruptus), spermicides 
only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception.
b.Male condom and female condom should not be used together (due to risk of failure with friction).
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 102Collection of Pregnancy Information
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure wou ld be a case involving direct contact 
[CONTACT_4490] a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to th e 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy .
If a participant or participant ’s partner becomes or is found to be pregnant during the 
participant ’s treatment with the investigational product, the investigator must report this 
information to [COMPANY_007] Safety  on the CT SAE Report Form and an EDP supplemental form, 
regardless of whether an SAE has occurred.  In addition, the investigator must submit 
information regarding environmental exposur e to a [COMPANY_007] product in a pregnant woman (eg, a 
participant reports that she is pregnant and has been exposed to a cy totoxic product by  
[CONTACT_4691][INVESTIGATOR_4598]) to [COMPANY_007] Safety using the EDP supplemental form.  This must be done 
irrespective of whether an AE has occurred and within 24 hours of awareness of the 
exposure.  The information submitted should include the anticipated date of delivery  (see 
below for information related to termination of pregnancy ).
Follow -up is conducted to obtain general informat ion on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP supple mental form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit yof the terminated fetus should be assessed by  [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pre gnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 103Additional information about pregnancy  outcomes that are reported to [COMPANY_007] Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_627083]. 
Additional information regarding the EDP may  be requested b y the sponsor.  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 104 
 
 
 
 
 
 
 
 
 
 CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE].6. Appendix 6: Liver Safety: Suggested Actions and Follow -up Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some participants, transaminase elev ations are a harbinger of a 
more serious potential outcome.  These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as drug -induced 
liver injury  (DILI).  Participants who experience a transaminase elevation above 3 times the 
upper limit of normal (× ULN) should be monitored more frequentl y to determine if they  are 
an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alan ine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 × ULN) b y several 
days or weeks.  The increase in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are still elevated 
above 3 × ULN (ie, AST/AL T and TBili values will be elevated within the s ame laboratory  
sample).  In rare instances, by  [CONTACT_22858], AST/AL T values might 
have decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili th at meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of la boratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions.  Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 × ULN AND a TBili value 
>2×ULN with no evide nce of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participants with baseline AST OR ALT OR TBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN or if the value reaches >3 ×ULN 
(whichever is smaller).
PF-[ADDRESS_627084]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_627085] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, creatine kinase (CK), direct and 
indirect bilirubin, gamma -glutam yl transferase (GGT), prothrombin time (PT)/international 
normalized ratio (INR), total bile acids, and alkaline phosphatase.  Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen (either b y itself or as a coformulated 
product in prescription or over -the-counter medications), recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected.  Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging ( eg, biliary  tract) and collection of 
serum sample for acetaminophen drug and/or protein adduct levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be cons idered potential DILI (Hy ’s law) cases if no 
other reason for the liver function test (LFT) abnormalities has y et been found.  Such 
potential DILI (Hy ’s law) cases are to be reported as SAEs, irrespective of availability  of all 
the results of the investiga tions performed to determine etiology  of the LFT abnormalities. 
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE].7. Appendix 7: ECG Fin dings of Potential Clinical Concern
ECG Findings That May Qualify as Adverse Events (AEs)
Marked sinus brad ycardia (rate <40 beats per minute ( bpm)) lasting minutes.
New PR interval prolongation >280 msec.
New prolongation of QTcF to >480 msec (absolute) or by ≥60msec from baseline.
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: 
ie,rate <120 bpm.
New -onset t ypeI second -degree (Wenckebach) AV block of >30 seconds’ 
duration.
Frequent premature ventricu lar contraction/ complexes [per Abbreviations] (PVCs),
triplets, or short intervals (<30 seconds) of consecutive ventricular complexes.
ECG Findings That May Qualify as Serious Adverse Events (SAEs)
QTcF prolongation >500 msec.
New ST -Tchanges suggestive of myocardial ischemia.
New -onset left bundle branch block (QRS >120 msec).
New -onset right bundle branch block (QRS >120 msec).
Symptomatic brady cardia. 
Asystole:
In awake, s ymptom -free patients in sinus rhy thm, with documented period s of 
asystole ≥3.0 seconds or any  escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node; 
In awake, s ymptom -free patients with atrial fibrillation and brad ycardia with 
[ADDRESS_627086] 5 seconds or longer; 
Atrial flutter or f ibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained supraventricular tach ycardia (rate >120 bpm) (“sustained” = short 
duration with relevant symptoms or lasting >1 minute).
Ventricular rh ythms >30 seconds’ duration, includin g idioventricular rh ythm (rate 
<40 bpm), accelerated idioventricular rh ythm (40< x <100), and 
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 108monomorphic/poly morphic ventricular tach ycardia >100 bpm (such as torsades de 
pointes).
Type IIsecond -degree (Mobitz II) AVblock.
Complete (third- degree) heart block.
ECG Findings That Qualify as Serious Adverse Events
Change in pattern suggestive of new m yocardial infarction. 
Sustained ventricular tachy arrhy thmias (>30 seconds’ duration).
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.
Ventricular fibrillation/flutter.
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and [COMPANY_007] study team, and not to be 
considered as all inclusive of what to be repo rted as AEs/SAEs.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE].8. Appendix 8 : Prohibited Concomitant Medications
This is not an all -inclusive list.  Study personnel should stay  current and consult with their 
pharmacy  to exclude all concomitant medications that fall into the categories in the list 
below: 
CYP1A2, CYP3A4, CYP2D6 
Inhibitors (Moderate to Strong)CYP1A2, CYP3A4, 
Inducers (Moderate to 
Strong)MATE substrates 
with Narrow 
Therapeutic Index
CYP 1A2 CYP 1A2
Ciprofloxacin Pheny toin Dofetilide
Clinafloxacin Rifampin
Enoxacin Ritonavir
Fluvoxamine Teriflunomide
Oltipraz
Rofecoxib
Zafirlukast
Etintidine
Idrocilamide
Methoxsalen
Mexiletine
Pheny lpropanolamine
Pi[INVESTIGATOR_488030] 2D6
Quinidine
Fluoxetine
Dacomitinib
Paroxetine
Buproprion
Cinacalcet
Terbinafine
Tipranavir
Moclobemide
Rolapi[INVESTIGATOR_488031]-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 110CYP1A2, CYP3A4, CYP2D6 
Inhibitors (Moderate to Strong)CYP1A2, CYP3A4, 
Inducers (Moderate to 
Strong)MATE substrates 
with Narrow 
Therapeutic Index
CYP3A4 CYP3A4
Viekira pak Rifampin
Indinavir Mitotane
Tipranavir Avasimibe
Ritonavir Pheny toin
Cobicistat Carbamazepi[INVESTIGATOR_488032]. John’s wort
Telaprevir Rifabutin
Danoprevir Phenobarbital
Elvitegravir
Saquinavir Semagacestat
Lopi[INVESTIGATOR_488033]***, Marmalade Modafanil
Conivaptan Etravirine
Nefazodone Lersivirine
Nelfinavir
Saquinavir
Idelalisib
Boceprevir
Erythrom ycin
Fluconazole
Atazanavir
Darunavir
Diltiazem
Dronedarone
Crizotinib
Aprepi[INVESTIGATOR_488034]-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 111CYP1A2, CYP3A4, CYP2D6 
Inhibitors (Moderate to Strong)CYP1A2, CYP3A4, 
Inducers (Moderate to 
Strong)MATE substrates 
with Narrow 
Therapeutic Index
Nilotinib
Tofisopam
Cyclosporine
Ciprofloxacin
Isavuconazole
Cimetidine
All prohibited drugs that are CYP1A2, CYP3A and CYP2D6 inhibitors require at least a 7 day or 
5half-lives (whichever is longer) prior to the first dose of study drug.  Note: Amiodarone requires 
discontinuation at least 290 days (~5 half-lives, half -life averages ~58 days) prior to the first dose of IP.
All prohibited drugs that are CYP1A2 and CYP3A inducers require at least a 28 day or 5 half-lives 
(whichever is longer) prior to the first dose of IP.
***It is recommended that subjects avoid excessive consumption of grapefruit juice exceeding 8 ounces 
(~240 mL) total in a day while in the study.
In a situation where appropriate m edical care of a subje ct requires the use of a prohibited 
inhibitor or inducer:
Moderate to potent inhibitors of CYP1A2, CYP3A and CYP2D6 and inducers of CYP1A2 and CYP3A are 
not permitted in the study EXCEPT in emergency situations requiring no more than one day of 
administration.  Note: Amiodarone and mitotane are not permitted for any duration due to their long 
half-lives.   Topi[INVESTIGATOR_2855] (including skin or mucous membranes) application of antimicrobial and antifungal 
medications is permitted.
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE].9. Appendix 9 : Columbia Suicide Severity Rating Scale (C -SSRS) for Screening and 
Baseline Visit 

PF-[ADDRESS_627087] -baseline visits “since last visit version”:

PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 115

PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE].10. Appendix 10: Psoriasis Symptom Inventory (PSI) (Daily Assessment)

PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 117Psoriasis Symptom Inventory (PSI)- 7 day

PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE].11. Appendix 11: Peak Pruritus Numeric Rating Scale (PP -NRS)
CENTER SUBJECT ID
Protocol ID:  ________________
DATE OF VISIT
- -
dd MMM yyyy
Visit:  
_______________________________
PEAK PRURITUS -NRS
(1) NOT DONE Language administered:     (44) English for [LOCATION_003]
On a scale of 0 to 10, with 0 being “no itch” and 10 being “worst itch imaginable”, how 
would y ou rate y our itch at the worst moment during the previous 24 hours?
[ADDRESS_627088] 
itch 
imaginable
Simpson E, Beck L, Abhijit G, et al. Defining a responder on the Peak Pruritus Numerical Rating Scale (NRS) 
in patients with moderate -to-severe atopic dermatitis: Detailed analysis from randomized trials of dupi[INVESTIGATOR_12458] . 
JAm Acad of Dermatol 2017; 76:AB93.
Yosipovitch G, Reaney M, Mastey V, et al. Validation of the peak pruritus numerical rating scale: Results from 
clinical studies of dupi[INVESTIGATOR_488035].  J Am Acad of 
Derm atol 2017; 76:AB278.
©Regeneron Pharmaceuticals, Inc. and [COMPANY_011] (2017) .
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 119CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 120CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 121 CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 122CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 123CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 124CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 125CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 126CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 127CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 128
CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page 129CCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE].17. Appendix 17: Physician Global Assessment

PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE].18. Appendix 18:eGFR Calculations
The estimated GFR (eGFR) will be calculated using the set of equations developed b y the 
Chronic Kidney  Disease Epi[INVESTIGATOR_8849] (CKD -EPI).
CKD -EPI 2009Scr
If female and serum creatinine ( SCr)is≤0.7 mg/dL:
GFR (mL/min/1.73 m2) = 144 x (Scr/0.7)–0.329 x 0.993age (x 1.159, if black).
If female and SCr is >0.7 mg/dL :
GFR (mL/min/1.73 m2) = 144 x (Scr/0.7)–1.209x 0.993age(x 1.159, if black) .
If male and SCr is ≤0.9 mg/dL :
GFR (mL/min/1.73 m2) = 141 x (Scr/0.9) –0.411x 0.993age(x 1.159, if black) .
If male and SCr is >0.9 mg/dL :
GFR (mL/min/1.73 m2) = 141 x (Scr/0.9) –1.209x 0.993age(x 1.159, if black) .
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE].19. Appendix 19: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
Abs Absolute
ADA antidrug antibodies
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the curve
AUC 24 area under the concentration time curve from zero to 24 hours after 
single dose
AV Atrioventricular
BA Bioavailability
β-hCG beta-human chorionic gonadotropin
BID Two times per day
BMI Body mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD-EPI [INVESTIGATOR_488036]/F apparent oral clearance
Cmax Total maximum observed concentration
CO 2 carbon dioxide (bicarbonate)
CONSORT Consolidated Standards of Reporting Trials
CRF case report form
CRO contract research organization
CSA clinical study agreement
CSR clinical study report
C-SSRS Columbia Suicide Severity Rating Scale
CT clinical trial
DILI drug-induced liver injury
DMC data monitoring committee
DNA deoxyribonucleic acid
DU dispensable unit
EBV epstein barr virus
EC ethics committee
ECG electrocardiogramCCICCICCI
PF-[ADDRESS_627089]
HIV human immunodeficiency virus
HRQoL Health related quality of life
HRT hormone replacement therapy
IB investigator’s brochure
IC50 50% inhibitory concentration
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IFN interferon
IGRA interferon gamma release assay
IMP investigational medicinal product
IND investigational new drug 
INR international normalized ratio
IP investigational product
IP manual investigational product manual
IRB institutional review board
IRC internal review committee
IRT interactive response technology
IUD intrauterine deviceCCICCI
PF-[ADDRESS_627090]
MAD Multiple ascending dose
MATE1 multidrug and toxin extrusion protein
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MDR1 multidrug resistant protein 1
MMR Measles, mumps, rubella
MRI Magnetic resonance imaging
MRP2 multidrug resistance-associated protein
msec millisecond 
N/A not available 
NIMP noninvestigational medicinal product
NOAEL no-observed-adverse-effect level
NTCP sodium/taurocholate co-transporting polypeptide
OATP organic anion transporting polypeptide
OC oral contraceptives
OCT organic cation transporter
PASI Psoriasis Area and Severity Index
PCD primary completion date
PCP Primary care physician
PCR Polymerase chain reaction
PD pharmacodynamic(s)
PGA Physicians global assessment
P-gp P glycoprotein
PI [INVESTIGATOR_19959](s)
PP-NRS Peak-Pruritus Numerical Rating Scale
PR Pulse rate
PRO Patient reported outcome
PSI Psoriasis symptom inventory
pSTAT Phosphorylated signal transducer and activator of transcription
PT prothrombin time
PUVA Psoralen + UVA phototherapy
PVC premature ventricular contraction/complexCCICCI
PF-[ADDRESS_627091]
QFT G QuantiFERONR TB Gold
QoL Quality of Life
QTc corrected QT
QTcF corrected QT (Fridericia method)
qual qualitative
RBC red blood cell
RNA ribonucleic acid
SAD Single ascending dose
SAE serious adverse event
SAP statistical analysis plan
SCr Serum creatinine
SDD Spray dried dispersion
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safety document
SToD study team on demand
S[LOCATION_003]R suspected unexpected serious adverse reaction
TB Tuberculosis
TBili total bilirubin
TEAE Treatment emergent adverse event
TNF Tumor necrosis factor
TYK2 tyrosine kinase [ADDRESS_627092] upper limit of normal
US [LOCATION_002]
UVB Ultraviolet band
Vss Apparent volume of distribution at steady state
VTE venous thromboembolic events
WBC white blood cell
WOCBP woman of childbearing potentialCCI
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE].REFERENCES
1. Feldman SR, Goffe B, Rice G, Mitchell M, Kaur M, Robertson D, Sierka D, Bourret JA, 
Evans TS, and Gottlieb A. The Challenge of Managing Psoriasis: Unmet Medical Needs 
and Stakeholder Perspectives. Am Health Drug Benefits. 2016 Dec; 9(9):504-513. 
2. Farhad S, Khoshmirsafa M, Aazami H,  Mohsenzadegan M, Sedighi G and Bahar M. 
The role of JAK -STAT signaling pathway  and its regulators in the fate of T helper cells 
Cell Commun Signal. 2017; 15: 23.
3. Floss DM, Klöcker T, Schröder J, L amertz L , Mrotzek S, Str obl B, Herman H, and 
Schellera J. Defining the functional binding sites of interleukin 12 receptor β1 and 
interleukin 23 receptor to Janus kinases. Mol Biol Cell. 2016 Jul 15; 27(14):2301–2316.
4. Tesmer LA, Lund y SK, Sarkar S, and Fox DA. Th17 cells in human disease Th17 cells 
in human disease. Immunol Rev. 2008 Jun; 223:87 -113.
5. Zambrano -Zaragoza JF, Romo-Martínez EJ, Durán-Avelar J, García- Magallanes N, and 
Vibanco -Pérez N. Th17 Cells in Autoimmune and I nfectious Diseases Int J 
Inflam.2014; 2014: 651503.
6. Suomela S, Kainu K, Onkamo P, Tiala I, Himberg J, Koskinen L , Snellman E, 
Karvonen SL, Karvonen J, Uurasmaa T, Reunala T, Kivikäs K, Jansén CT, Holopainen 
P, Elomaa O, Kere J, Saarialho- Kere U. Clinical associations of the risk alleles of HLA -
Cw6 and CCHCR 1*WWCC in psoriasis. Acta Derm Venereol. 2007;87(2):127-34.
7. Beatrice Marinoni, Angela Ceribelli, Marco S. Massarotti, and Carlo Selmi The Th17 
axis in psoriatic disease: pathogenetic and therapeutic implications Auto Immun 
Highlights. 2014 Jun; 5(1): 9 –19.
8. Papp et al. Phase 2 Trial of Selective Ty rosine Kinase 2 Inhibition in Psoriasis; The 
New England Journal of Medicine. 2018; 379:1313-1321.
9. Kim and Krueger. Highly  Effective New Treatments for Psoriasis Target the 
IL-23/Ty pe 17 T Cell Autoimmune Axis .Annu.Rev. Med. 2017; 65: 255 -269.
10. Long CC, Finlay  AY, Averill RW. The rule of hand: 4 hand areas = 2FTU = 1g. Arch 
Dermatol 1992;128 (8):1129-30.
11. Posner K, Brown GK, Stanley  B, Brent DA, Yershova KV, Oquendo MA, Currier GW, 
Melvin GA, Greenhill L , Shen S, Mann JJ. The Columbia –Suicide Severity  Rating 
Scale: Initial Validity  and I nternal Consistency  Findings From Three Multisite Studies 
With Adolescents and Adults. Ameri can Journal of Psy chiatry . 168:1266–77.
12. Zhu Y, Ye X, Zhu B, et al. Comparisons between the 2 012 New CKD -EPI (Chronic 
Kidney Disease Epi[INVESTIGATOR_8849]) Equations and Other Four Approved 
Equations. PL oSONE 9(1): e84688. 
PF-06826647
Protocol C2501004
Final Protocol Amendment 1, 01 October 2019
PFIZER CONFIDENTIAL
Page [ZIP_CODE]. Wilson, H. D. et al. Reliability  and Validity  of the Psoriasis Sy mptom Inventory  in 
Patients With Psoriatic Arthritis. Arthritis C are & Research 67,1750 -1756,(2015).
14. Stander, S. et al. Validation of the Itch Severity  Item as a Measurement Tool for 
Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program. Acta 
dermato- venereologica 98, 340 -345,(2018).
15. Kimball, A. B. et al. Ps ychometric properties of the I tch Numeric Rating Scale in 
patients with moderate -to-severe plaque psoriasis. The British Journal of Dermatology  
175, 157 -162,(2016).
16. Finlay  AY, Khan GK. Dermatology  Life Quality  Index (DLQI) –a simp le practical 
measure for routine clinical use. Clin Exp Dermatol 199 4; 19 (3):210-6.
17. Ware, J. et al. Development. User's Manual for the SF- 36v2® Health Survey . Lincoln 
(RI): Quality Metric Incorporated (2007).
18. EuroQol --a new facility  for the measurement of h ealth -related quality  of life. Health 
policy  (Amsterdam, N etherlands) 16, 199 -208; (1990).
19. Herdman, M. et al. Development and preliminary  testing of the new five- level version 
of EQ -5D (EQ -5D- 5L). Quality  of life research : an international journal of quali ty of 
life aspects of treatment, care and rehabilitation 20, 1727 -1736,(2011).
20. Janssen, M. F. et al. Measurement properties of the EQ-5D- 5L compared to the EQ -5D-
3L across eight patient groups: a multi -country  study . Quality  of life research: an 
international journal of quality  of life aspects of treatment, care an d rehabilitation 
22,1717 -1727,(2013).